US9670210B2 - Cyclopropylamines as LSD1 inhibitors - Google Patents
Cyclopropylamines as LSD1 inhibitors Download PDFInfo
- Publication number
- US9670210B2 US9670210B2 US14/620,903 US201514620903A US9670210B2 US 9670210 B2 US9670210 B2 US 9670210B2 US 201514620903 A US201514620903 A US 201514620903A US 9670210 B2 US9670210 B2 US 9670210B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- methyl
- aryl
- cycloalkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *.B.C.C*C.CC.CC.CC.[4*]C.[5*]C([6*])(CC)CC1CC1C Chemical compound *.B.C.C*C.CC.CC.CC.[4*]C.[5*]C([6*])(CC)CC1CC1C 0.000 description 15
- AFJPYYFVTPYDOQ-UHFFFAOYSA-N CC(C)N1CCC2(C1)OC(=O)C1=C2C=CC=C1.CC(C)N1CCC2(CC1)CNC1=C2C=CC=C1.CC(C)N1CCCC2(CCNC2=O)C1 Chemical compound CC(C)N1CCC2(C1)OC(=O)C1=C2C=CC=C1.CC(C)N1CCC2(CC1)CNC1=C2C=CC=C1.CC(C)N1CCCC2(CCNC2=O)C1 AFJPYYFVTPYDOQ-UHFFFAOYSA-N 0.000 description 3
- UGOCYDJBTGPJEJ-UHFFFAOYSA-N CC(C)N1CCC2(CC1)CNC1=C2C=CC=C1.CC(C)N1CCCC2(CCNC2=O)C1 Chemical compound CC(C)N1CCC2(CC1)CNC1=C2C=CC=C1.CC(C)N1CCCC2(CCNC2=O)C1 UGOCYDJBTGPJEJ-UHFFFAOYSA-N 0.000 description 3
- WVBLAQSOEXCAPQ-UHFFFAOYSA-N CC(C)(C)OC(=O)C1(C(=O)O)CCCC1 Chemical compound CC(C)(C)OC(=O)C1(C(=O)O)CCCC1 WVBLAQSOEXCAPQ-UHFFFAOYSA-N 0.000 description 2
- DTJOPWCWQOHWNZ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(C=O)(COCC2CCC2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)(COCC2CCC2)CC1 DTJOPWCWQOHWNZ-UHFFFAOYSA-N 0.000 description 2
- JLJSLCJLESWFPT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CO)(CC2=CC=C(F)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CO)(CC2=CC=C(F)C=C2)CC1 JLJSLCJLESWFPT-UHFFFAOYSA-N 0.000 description 2
- MMFGVECXGWQWKF-UHFFFAOYSA-N CN(CCC1)CC1(CCN1)C1=O Chemical compound CN(CCC1)CC1(CCN1)C1=O MMFGVECXGWQWKF-UHFFFAOYSA-N 0.000 description 2
- MHWMFBBXGBLALT-UHFFFAOYSA-N COC(=O)C1(C(=O)OC(C)(C)C)CCCC1 Chemical compound COC(=O)C1(C(=O)OC(C)(C)C)CCCC1 MHWMFBBXGBLALT-UHFFFAOYSA-N 0.000 description 2
- PKXYOOJRGUXESH-UHFFFAOYSA-N COCC1(CO)CCNCC1 Chemical compound COCC1(CO)CCNCC1 PKXYOOJRGUXESH-UHFFFAOYSA-N 0.000 description 2
- IBMQRNQGGPQIIS-BPGUCPLFSA-N C=CCOC(=O)N(CC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 IBMQRNQGGPQIIS-BPGUCPLFSA-N 0.000 description 1
- FRJFCSJOEMPIAY-WUBHUQEYSA-N C=CCOC(=O)N(CC1(CC2=CN=C(Cl)C=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(CC2=CN=C(Cl)C=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 FRJFCSJOEMPIAY-WUBHUQEYSA-N 0.000 description 1
- RPHOXQFBJRWFAC-OZAIVSQSSA-N C=CCOC(=O)N(CC1(CC2=CN=C(OC)C=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(CC2=CN=C(OC)C=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 RPHOXQFBJRWFAC-OZAIVSQSSA-N 0.000 description 1
- XZNDHXYGTMNPKR-BPGUCPLFSA-N C=CCOC(=O)N(CC1(CO)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(CO)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 XZNDHXYGTMNPKR-BPGUCPLFSA-N 0.000 description 1
- FPJFALITWRJNOP-WUBHUQEYSA-N C=CCOC(=O)N(CC1(COC2=CC=C(F)C=N2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(COC2=CC=C(F)C=N2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 FPJFALITWRJNOP-WUBHUQEYSA-N 0.000 description 1
- JBEDUZMRILKGOI-FOIFJWKZSA-N C=CCOC(=O)N(CC1(COC2=CC=C(F)C=N2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(COC2=CC=C(F)C=N2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 JBEDUZMRILKGOI-FOIFJWKZSA-N 0.000 description 1
- CJBTUMAUQQMIAL-XMMISQBUSA-N C=CCOC(=O)N(CC1(COC2CCCCC2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(COC2CCCCC2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 CJBTUMAUQQMIAL-XMMISQBUSA-N 0.000 description 1
- CXVREFRWJPTTQN-OZAIVSQSSA-N C=CCOC(=O)N(CC1(COCC2CCC2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound C=CCOC(=O)N(CC1(COCC2CCC2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 CXVREFRWJPTTQN-OZAIVSQSSA-N 0.000 description 1
- LXCGMXUNXRWYCI-GFOWMXPYSA-N CC(=O)N(CC1(C)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(C)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 LXCGMXUNXRWYCI-GFOWMXPYSA-N 0.000 description 1
- HPDKSMFPDQYKDD-ZYMOGRSISA-N CC(=O)N(CC1(C)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(C)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 HPDKSMFPDQYKDD-ZYMOGRSISA-N 0.000 description 1
- JUZYCHVCRVYDOP-PLYLYKGUSA-N CC(=O)N(CC1(CC2=CC=C(CC#N)C=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=C(CC#N)C=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 JUZYCHVCRVYDOP-PLYLYKGUSA-N 0.000 description 1
- ZECGNIGPWRDJJB-NLIBRCFJSA-N CC(=O)N(CC1(CC2=CC=C(CC#N)C=C2)CCN(CC2(C(=O)OC(C)(C)C)CC2)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=C(CC#N)C=C2)CCN(CC2(C(=O)OC(C)(C)C)CC2)CC1)[C@@H]1CC1C1=CC=CC=C1 ZECGNIGPWRDJJB-NLIBRCFJSA-N 0.000 description 1
- GPXIFCZWDUJAFV-WUBHUQEYSA-N CC(=O)N(CC1(CC2=CC=C(CC#N)C=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=C(CC#N)C=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 GPXIFCZWDUJAFV-WUBHUQEYSA-N 0.000 description 1
- UXJNYWRSMKKYCL-FXDYGKIASA-N CC(=O)N(CC1(CC2=CC=C(F)C=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=C(F)C=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 UXJNYWRSMKKYCL-FXDYGKIASA-N 0.000 description 1
- GEDRLVFEYNPYGE-OZAIVSQSSA-N CC(=O)N(CC1(CC2=CC=C(F)C=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=C(F)C=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 GEDRLVFEYNPYGE-OZAIVSQSSA-N 0.000 description 1
- ZWKNVLGGORUDEX-FXDYGKIASA-N CC(=O)N(CC1(CC2=CC=CC(Br)=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=CC(Br)=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 ZWKNVLGGORUDEX-FXDYGKIASA-N 0.000 description 1
- GMIYMUVZLLYUSW-SSYAZFEXSA-N CC(=O)N(CC1(CC2=CC=CC(C#N)=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=CC(C#N)=C2)CCN(C(=O)OC(C)(C)C)CC1)[C@@H]1CC1C1=CC=CC=C1 GMIYMUVZLLYUSW-SSYAZFEXSA-N 0.000 description 1
- NCWMFUILUQMUAU-XMMISQBUSA-N CC(=O)N(CC1(CC2=CC=CC(C#N)=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(CC2=CC=CC(C#N)=C2)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 NCWMFUILUQMUAU-XMMISQBUSA-N 0.000 description 1
- HSWPQGRNYSPQGQ-LWMIZPGFSA-N CC(=O)N(CC1(COC2=CC=CC=C2F)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1(COC2=CC=CC=C2F)CCNCC1)[C@@H]1CC1C1=CC=CC=C1 HSWPQGRNYSPQGQ-LWMIZPGFSA-N 0.000 description 1
- FOBNGANCKQEYAX-UHFFFAOYSA-N CC(=O)N(CC1CN(C(=O)OC(C)(C)C)C1)C1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1CN(C(=O)OC(C)(C)C)C1)C1CC1C1=CC=CC=C1 FOBNGANCKQEYAX-UHFFFAOYSA-N 0.000 description 1
- QTZVOWDQKUEVFV-UHFFFAOYSA-N CC(=O)N(CC1CNC1)C1CC1C1=CC=CC=C1 Chemical compound CC(=O)N(CC1CNC1)C1CC1C1=CC=CC=C1 QTZVOWDQKUEVFV-UHFFFAOYSA-N 0.000 description 1
- FSQXAHDYGFYONQ-UHFFFAOYSA-N CC(C)(C)OC(=O)C1(C(=O)O)CC1 Chemical compound CC(C)(C)OC(=O)C1(C(=O)O)CC1 FSQXAHDYGFYONQ-UHFFFAOYSA-N 0.000 description 1
- BFRXFYLTDGXBMV-UHFFFAOYSA-N CC(C)(C)OC(=O)C1(C=O)CC1 Chemical compound CC(C)(C)OC(=O)C1(C=O)CC1 BFRXFYLTDGXBMV-UHFFFAOYSA-N 0.000 description 1
- NSPICERRKQVJIB-UHFFFAOYSA-N CC(C)(C)OC(=O)C1(C=O)CCCC1 Chemical compound CC(C)(C)OC(=O)C1(C=O)CCCC1 NSPICERRKQVJIB-UHFFFAOYSA-N 0.000 description 1
- NWNFJDMTURMKCB-UHFFFAOYSA-N CC(C)(C)OC(=O)C1(CO)CC1 Chemical compound CC(C)(C)OC(=O)C1(CO)CC1 NWNFJDMTURMKCB-UHFFFAOYSA-N 0.000 description 1
- WERJMFAMAFYNBN-UHFFFAOYSA-N CC(C)(C)OC(=O)C1(CO)CCCC1 Chemical compound CC(C)(C)OC(=O)C1(CO)CCCC1 WERJMFAMAFYNBN-UHFFFAOYSA-N 0.000 description 1
- SFBOXTFKWDOWBW-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound CC(C)(C)OC(=O)N1CC(CCC2CC2C2=CC=CC=C2)C1 SFBOXTFKWDOWBW-UHFFFAOYSA-N 0.000 description 1
- MOCDOWAEFZUUIX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(C=O)(CC#N)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)(CC#N)CC1 MOCDOWAEFZUUIX-UHFFFAOYSA-N 0.000 description 1
- JZFTZADOIYBWMG-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(C=O)(CC2=CC=C(F)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)(CC2=CC=C(F)C=C2)CC1 JZFTZADOIYBWMG-UHFFFAOYSA-N 0.000 description 1
- ZPTFGPNXPKJCIT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC#N)(C(=O)O)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC#N)(C(=O)O)CC1 ZPTFGPNXPKJCIT-UHFFFAOYSA-N 0.000 description 1
- OKXLQIKVLTYYLC-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC#N)(CCC2CC2C2=CC=CC=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC#N)(CCC2CC2C2=CC=CC=C2)CC1 OKXLQIKVLTYYLC-UHFFFAOYSA-N 0.000 description 1
- FOOSZIKQCZTPOH-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC#N)(CN(C(=O)C(F)(F)F)C2CC2C2=CC=CC=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC#N)(CN(C(=O)C(F)(F)F)C2CC2C2=CC=CC=C2)CC1 FOOSZIKQCZTPOH-UHFFFAOYSA-N 0.000 description 1
- VGBWCBLJHASAOX-AVJYQCBHSA-N CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(CC2=CC=C(CC#N)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(CC2=CC=C(CC#N)C=C2)CC1 VGBWCBLJHASAOX-AVJYQCBHSA-N 0.000 description 1
- JDUQPIXUVVEMAD-XQZUBTRRSA-N CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(CC2=CC=C(F)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(CC2=CC=C(F)C=C2)CC1 JDUQPIXUVVEMAD-XQZUBTRRSA-N 0.000 description 1
- SFJBQZBZQFIZSZ-WTQRLHSKSA-N CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(CC2=CN=C(Cl)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(CC2=CN=C(Cl)C=C2)CC1 SFJBQZBZQFIZSZ-WTQRLHSKSA-N 0.000 description 1
- CEOMUKLFANLTPB-MIHMCVIASA-N CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(COCC2CCC2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC[C@@H]2CC2C2=CC=CC=C2)(COCC2CCC2)CC1 CEOMUKLFANLTPB-MIHMCVIASA-N 0.000 description 1
- ZREHGTHLAMYLRJ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CO)(CC#N)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CO)(CC#N)CC1 ZREHGTHLAMYLRJ-UHFFFAOYSA-N 0.000 description 1
- PLORMTUPTKNKPX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CO)(COC2=CC=CC=C2F)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CO)(COC2=CC=CC=C2F)CC1 PLORMTUPTKNKPX-UHFFFAOYSA-N 0.000 description 1
- RTCMKZLOTWUDFP-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CO)(COC2CCCCC2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CO)(COC2CCCCC2)CC1 RTCMKZLOTWUDFP-UHFFFAOYSA-N 0.000 description 1
- SXADNDQRJLPLEL-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CO)(COCC2CCC2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CO)(COCC2CCC2)CC1 SXADNDQRJLPLEL-UHFFFAOYSA-N 0.000 description 1
- FOYSLKQLGXTBRZ-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CN(C(C2)C2c2ccccc2)C(C(F)(F)F)=O)C1)=O Chemical compound CC(C)(C)OC(N1CC(CN(C(C2)C2c2ccccc2)C(C(F)(F)F)=O)C1)=O FOYSLKQLGXTBRZ-UHFFFAOYSA-N 0.000 description 1
- ZLBZJYJWNMJTAF-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(CC#N)(CNC(C2)C2c2ccccc2)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(CC#N)(CNC(C2)C2c2ccccc2)CC1)=O ZLBZJYJWNMJTAF-UHFFFAOYSA-N 0.000 description 1
- WSTYMWZBJADAAV-UHFFFAOYSA-N CC(C)N(CC1)CC1(c1ccccc11)OC1=O Chemical compound CC(C)N(CC1)CC1(c1ccccc11)OC1=O WSTYMWZBJADAAV-UHFFFAOYSA-N 0.000 description 1
- RLXZOSVYAJDWKK-FIWHBWSRSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2(N)CCCC2)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2(N)CCCC2)CC1 RLXZOSVYAJDWKK-FIWHBWSRSA-N 0.000 description 1
- DXPCXMSWZMWPQO-QNSVNVJESA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CC=C(N)N=N2)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CC=C(N)N=N2)CC1 DXPCXMSWZMWPQO-QNSVNVJESA-N 0.000 description 1
- OAXYZEIFOYSCJL-DUSLRRAJSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN=C(N)N=C2)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN=C(N)N=C2)CC1 OAXYZEIFOYSCJL-DUSLRRAJSA-N 0.000 description 1
- NVOLKEOPBJFVFA-TZHYSIJRSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CNN=C2N)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CNN=C2N)CC1 NVOLKEOPBJFVFA-TZHYSIJRSA-N 0.000 description 1
- PYHUTGMBAILFLC-MRTLOADZSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 PYHUTGMBAILFLC-MRTLOADZSA-N 0.000 description 1
- JTHLINMUOUUADB-MRTLOADZSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 JTHLINMUOUUADB-MRTLOADZSA-N 0.000 description 1
- UURVFPIIILLNQA-FIWHBWSRSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 UURVFPIIILLNQA-FIWHBWSRSA-N 0.000 description 1
- SNKWNSCSMDWWJE-FIWHBWSRSA-N CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2=CN=C(N)N=C2)CC1 Chemical compound CC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2=CN=C(N)N=C2)CC1 SNKWNSCSMDWWJE-FIWHBWSRSA-N 0.000 description 1
- CGIFBUILSIFKPM-MIHMCVIASA-N CCC(=O)C1=NC(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)=CC=C1 Chemical compound CCC(=O)C1=NC(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)=CC=C1 CGIFBUILSIFKPM-MIHMCVIASA-N 0.000 description 1
- GUPNVEXNNSRLFV-UHFFFAOYSA-N CCC1(CO)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound CCC1(CO)CCN(C(=O)OC(C)(C)C)CC1 GUPNVEXNNSRLFV-UHFFFAOYSA-N 0.000 description 1
- VHELRLGQGUCVMK-UHFFFAOYSA-N CCC1(COC2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound CCC1(COC2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 VHELRLGQGUCVMK-UHFFFAOYSA-N 0.000 description 1
- LNFNUFHWICOMMN-UHFFFAOYSA-N CCC1(COCC2CCC2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound CCC1(COCC2CCC2)CCN(C(=O)OC(C)(C)C)CC1 LNFNUFHWICOMMN-UHFFFAOYSA-N 0.000 description 1
- KIMHOHJJIOGBEO-UHFFFAOYSA-N CCC1=CC=C(F)C=N1 Chemical compound CCC1=CC=C(F)C=N1 KIMHOHJJIOGBEO-UHFFFAOYSA-N 0.000 description 1
- ONQGUMRQIQRQNY-VQCQRNETSA-N CCOCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 Chemical compound CCOCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 ONQGUMRQIQRQNY-VQCQRNETSA-N 0.000 description 1
- MEZSFKNJCFYFNJ-ZMFCMNQTSA-N CCOCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound CCOCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 MEZSFKNJCFYFNJ-ZMFCMNQTSA-N 0.000 description 1
- ZOIVKPHWNRFHIG-UHFFFAOYSA-N CN(CC1)CC1(c1ccccc11)OC1=O Chemical compound CN(CC1)CC1(c1ccccc11)OC1=O ZOIVKPHWNRFHIG-UHFFFAOYSA-N 0.000 description 1
- QQKAQFCVBYIICJ-MRTLOADZSA-N CN1C=CC(C(=O)N2CCC(C)(CC[C@@H]3CC3C3=CC=CC=C3)CC2)=N1 Chemical compound CN1C=CC(C(=O)N2CCC(C)(CC[C@@H]3CC3C3=CC=CC=C3)CC2)=N1 QQKAQFCVBYIICJ-MRTLOADZSA-N 0.000 description 1
- HXDXRIDWGBQPJL-MRTLOADZSA-N CN1C=NC(C(=O)N2CCC(C)(CC[C@@H]3CC3C3=CC=CC=C3)CC2)=C1 Chemical compound CN1C=NC(C(=O)N2CCC(C)(CC[C@@H]3CC3C3=CC=CC=C3)CC2)=C1 HXDXRIDWGBQPJL-MRTLOADZSA-N 0.000 description 1
- WZMOMLKGYCUALE-LETIRJCYSA-N CNC(=O)C1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=N1 Chemical compound CNC(=O)C1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=N1 WZMOMLKGYCUALE-LETIRJCYSA-N 0.000 description 1
- WPFGPWQYBRZHPY-UHFFFAOYSA-N COC(=O)C1(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(C(=O)OC(C)(C)C)CC1 WPFGPWQYBRZHPY-UHFFFAOYSA-N 0.000 description 1
- RMPZPDNSMGBBAE-UHFFFAOYSA-N COC(=O)C1(C=O)CC1 Chemical compound COC(=O)C1(C=O)CC1 RMPZPDNSMGBBAE-UHFFFAOYSA-N 0.000 description 1
- ZWKZWJDTPRZFLV-UHFFFAOYSA-N COC(=O)C1(C=O)CCC1 Chemical compound COC(=O)C1(C=O)CCC1 ZWKZWJDTPRZFLV-UHFFFAOYSA-N 0.000 description 1
- ORSYDLVMTMZUFS-UHFFFAOYSA-N COC(=O)C1(C=O)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(C=O)CCN(C(=O)OC(C)(C)C)CC1 ORSYDLVMTMZUFS-UHFFFAOYSA-N 0.000 description 1
- UQRMOFVFJWSNEV-UHFFFAOYSA-N COC(=O)C1(CC#N)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(CC#N)CCN(C(=O)OC(C)(C)C)CC1 UQRMOFVFJWSNEV-UHFFFAOYSA-N 0.000 description 1
- ZHDJFSNBIIDNJJ-UHFFFAOYSA-N COC(=O)C1(CC2=CC=C(F)C=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(CC2=CC=C(F)C=C2)CCN(C(=O)OC(C)(C)C)CC1 ZHDJFSNBIIDNJJ-UHFFFAOYSA-N 0.000 description 1
- JRFIUVZBLYSGTN-MRTLOADZSA-N COC(=O)C1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 JRFIUVZBLYSGTN-MRTLOADZSA-N 0.000 description 1
- IAPUDFWXXVYPME-SSYAZFEXSA-N COC(=O)C1(CN2CCC(CC3=CC=C(F)C=C3)(CN(C(C)=O)[C@@H]3CC3C3=CC=CC=C3)CC2)CC1 Chemical compound COC(=O)C1(CN2CCC(CC3=CC=C(F)C=C3)(CN(C(C)=O)[C@@H]3CC3C3=CC=CC=C3)CC2)CC1 IAPUDFWXXVYPME-SSYAZFEXSA-N 0.000 description 1
- YLNAXTUVFOXHTI-UHFFFAOYSA-N COC(=O)C1(CO)CC1 Chemical compound COC(=O)C1(CO)CC1 YLNAXTUVFOXHTI-UHFFFAOYSA-N 0.000 description 1
- UQZQXEFGHRYLNJ-UHFFFAOYSA-N COC(=O)C1(CO)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(CO)CCN(C(=O)OC(C)(C)C)CC1 UQZQXEFGHRYLNJ-UHFFFAOYSA-N 0.000 description 1
- AAQPQHYQESFAPJ-UHFFFAOYSA-N COC(=O)C1(COC2=CC=CC=C2F)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(COC2=CC=CC=C2F)CCN(C(=O)OC(C)(C)C)CC1 AAQPQHYQESFAPJ-UHFFFAOYSA-N 0.000 description 1
- BVRQSFGGPOZVQL-UHFFFAOYSA-N COC(=O)C1(COCC2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COC(=O)C1(COCC2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 BVRQSFGGPOZVQL-UHFFFAOYSA-N 0.000 description 1
- YQUIEIPPSKDBHP-SSYAZFEXSA-N COC(=O)C1=CC(CC2(CN(C(C)=O)[C@@H]3CC3C3=CC=CC=C3)CCN(C(=O)OC(C)(C)C)CC2)=CC=C1 Chemical compound COC(=O)C1=CC(CC2(CN(C(C)=O)[C@@H]3CC3C3=CC=CC=C3)CCN(C(=O)OC(C)(C)C)CC2)=CC=C1 YQUIEIPPSKDBHP-SSYAZFEXSA-N 0.000 description 1
- FGFQJUOCBBUYTP-XMMISQBUSA-N COC(=O)C1=CC(CC2(CN(C(C)=O)[C@@H]3CC3C3=CC=CC=C3)CCNCC2)=CC=C1 Chemical compound COC(=O)C1=CC(CC2(CN(C(C)=O)[C@@H]3CC3C3=CC=CC=C3)CCNCC2)=CC=C1 FGFQJUOCBBUYTP-XMMISQBUSA-N 0.000 description 1
- AFCUVQZUNFDTPD-UHFFFAOYSA-N COC(=O)C1=CC=C(CN2CC(CN(C(C)=O)C3CC3C3=CC=CC=C3)C2)C=C1 Chemical compound COC(=O)C1=CC=C(CN2CC(CN(C(C)=O)C3CC3C3=CC=CC=C3)C2)C=C1 AFCUVQZUNFDTPD-UHFFFAOYSA-N 0.000 description 1
- KWNMPBHHMPXVQP-UHFFFAOYSA-N COC(=O)C1=CC=C(CN2CCC(=O)CC2)C=C1 Chemical compound COC(=O)C1=CC=C(CN2CCC(=O)CC2)C=C1 KWNMPBHHMPXVQP-UHFFFAOYSA-N 0.000 description 1
- PYVFADLTKICTOB-UHFFFAOYSA-N COC(=O)C1=CC=C(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)C=C1 Chemical compound COC(=O)C1=CC=C(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)C=C1 PYVFADLTKICTOB-UHFFFAOYSA-N 0.000 description 1
- YDJKULJUJJSIJN-UHFFFAOYSA-N COC1=C(NC(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C=CC=C1 Chemical compound COC1=C(NC(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C=CC=C1 YDJKULJUJJSIJN-UHFFFAOYSA-N 0.000 description 1
- DOIMEDAHJHDKJZ-NHQUYOMTSA-N COC1=CC(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC(C(=O)O)=CC=C3)CC2)=CC=C1 Chemical compound COC1=CC(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC(C(=O)O)=CC=C3)CC2)=CC=C1 DOIMEDAHJHDKJZ-NHQUYOMTSA-N 0.000 description 1
- MTTIPOOVRINBCR-RMVMEJTISA-N COC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 Chemical compound COC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 MTTIPOOVRINBCR-RMVMEJTISA-N 0.000 description 1
- OAEAPANASDKWST-CSMDKSQMSA-N COC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C=C1 Chemical compound COC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C=C1 OAEAPANASDKWST-CSMDKSQMSA-N 0.000 description 1
- JIYUOAKONVTYOS-UHFFFAOYSA-N COC1=CC=C(NC(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 Chemical compound COC1=CC=C(NC(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 JIYUOAKONVTYOS-UHFFFAOYSA-N 0.000 description 1
- VOENYKTVMYERDF-UHFFFAOYSA-N COC1=CC=CC(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 Chemical compound COC1=CC=CC(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 VOENYKTVMYERDF-UHFFFAOYSA-N 0.000 description 1
- YFBQVUBRXJMDCM-UHFFFAOYSA-N COC1=CC=CC(NC(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 Chemical compound COC1=CC=CC(NC(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 YFBQVUBRXJMDCM-UHFFFAOYSA-N 0.000 description 1
- UAUIOIZMQOLVKT-MIHMCVIASA-N COC1=NC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 Chemical compound COC1=NC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 UAUIOIZMQOLVKT-MIHMCVIASA-N 0.000 description 1
- NFVZWKPCRSYCTG-UHFFFAOYSA-N COC1CCCN(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C1 Chemical compound COC1CCCN(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C1 NFVZWKPCRSYCTG-UHFFFAOYSA-N 0.000 description 1
- YYWJEKAUHWKOFU-MUMRKEEXSA-N COCC(CN([C@H](C1)C1c1ccccc1)C(C(F)(F)F)=O)(CC1)CCN1C(c1c[nH]nc1)=O Chemical compound COCC(CN([C@H](C1)C1c1ccccc1)C(C(F)(F)F)=O)(CC1)CCN1C(c1c[nH]nc1)=O YYWJEKAUHWKOFU-MUMRKEEXSA-N 0.000 description 1
- ZBNKUMQFMLURKJ-GIBKCMNESA-N COCC(CN[C@H](C1)C1c1ccccc1)(CC1)CCN1C(N(CCC1)C[C@@H]1O)=O Chemical compound COCC(CN[C@H](C1)C1c1ccccc1)(CC1)CCN1C(N(CCC1)C[C@@H]1O)=O ZBNKUMQFMLURKJ-GIBKCMNESA-N 0.000 description 1
- KPAFHIZUZSMNJZ-UHFFFAOYSA-N COCC1(C(=O)N(C)OC)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COCC1(C(=O)N(C)OC)CCN(C(=O)OC(C)(C)C)CC1 KPAFHIZUZSMNJZ-UHFFFAOYSA-N 0.000 description 1
- MAPYKNWQCGBCES-UHFFFAOYSA-N COCC1(C(=O)OC)CCCCC1 Chemical compound COCC1(C(=O)OC)CCCCC1 MAPYKNWQCGBCES-UHFFFAOYSA-N 0.000 description 1
- OTKGORMFUITYIS-UHFFFAOYSA-N COCC1(C(C)=O)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COCC1(C(C)=O)CCN(C(=O)OC(C)(C)C)CC1 OTKGORMFUITYIS-UHFFFAOYSA-N 0.000 description 1
- FAZKLJRYRORBDF-HBYOEVMUSA-N COCC1(C(C)C[C@@H]2C[C@H]2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COCC1(C(C)C[C@@H]2C[C@H]2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 FAZKLJRYRORBDF-HBYOEVMUSA-N 0.000 description 1
- ZKOHYLXLFIQPNS-WXPBMIAQSA-N COCC1(C(C)C[C@@H]2C[C@H]2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(C(C)C[C@@H]2C[C@H]2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 ZKOHYLXLFIQPNS-WXPBMIAQSA-N 0.000 description 1
- FZEAMRDPTBCZJZ-LFZQMPOYSA-N COCC1(C(C)N(C(C)=O)[C@@H]2C[C@H]2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COCC1(C(C)N(C(C)=O)[C@@H]2C[C@H]2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 FZEAMRDPTBCZJZ-LFZQMPOYSA-N 0.000 description 1
- ANXXVCWNQXPDOP-AOWWOYQVSA-N COCC1(C(C)N(C(C)=O)[C@@H]2C[C@H]2C2=CC=CC=C2)CCNCC1 Chemical compound COCC1(C(C)N(C(C)=O)[C@@H]2C[C@H]2C2=CC=CC=C2)CCNCC1 ANXXVCWNQXPDOP-AOWWOYQVSA-N 0.000 description 1
- LENYLESHOWGJLW-UHFFFAOYSA-N COCC1(C=O)CCCCC1 Chemical compound COCC1(C=O)CCCCC1 LENYLESHOWGJLW-UHFFFAOYSA-N 0.000 description 1
- YUCUFZXASXWVJN-UHFFFAOYSA-N COCC1(C=O)CCN(CC2(C(=O)OC)CCC2)CC1 Chemical compound COCC1(C=O)CCN(CC2(C(=O)OC)CCC2)CC1 YUCUFZXASXWVJN-UHFFFAOYSA-N 0.000 description 1
- SFVYURIPVJCXEC-UHFFFAOYSA-N COCC1(CCC2CC2C2=C(OC)C=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(CCC2CC2C2=C(OC)C=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 SFVYURIPVJCXEC-UHFFFAOYSA-N 0.000 description 1
- XFXSYGOJAFTQFZ-UHFFFAOYSA-N COCC1(CCC2CC2C2=CC=C(C)C=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(CCC2CC2C2=CC=C(C)C=C2)CCN(CC2(C(=O)O)CCC2)CC1 XFXSYGOJAFTQFZ-UHFFFAOYSA-N 0.000 description 1
- UMOSBYGJRAIVNA-QSVWIEALSA-N COCC1(CC[C@@H]2CC2C2=C(F)C=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=C(F)C=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 UMOSBYGJRAIVNA-QSVWIEALSA-N 0.000 description 1
- NHJAASHBKHQDSH-MRTLOADZSA-N COCC1(CC[C@@H]2CC2C2=CC(F)=C(F)C=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC(F)=C(F)C=C2)CCN(CC2(C(=O)O)CCC2)CC1 NHJAASHBKHQDSH-MRTLOADZSA-N 0.000 description 1
- VIHXJZHFJBUDOG-YMBRHYMPSA-N COCC1(CC[C@@H]2CC2C2=CC=C(F)C=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=C(F)C=C2)CCN(CC2(C(=O)O)CCC2)CC1 VIHXJZHFJBUDOG-YMBRHYMPSA-N 0.000 description 1
- MCFZDGLVOZONKL-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2(C#N)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2(C#N)CC2)CC1 MCFZDGLVOZONKL-FIWHBWSRSA-N 0.000 description 1
- JRIUPYKIFZQNCB-MRTLOADZSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CC=C(N)N=N2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CC=C(N)N=N2)CC1 JRIUPYKIFZQNCB-MRTLOADZSA-N 0.000 description 1
- BADUZVJYQXNZNK-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(C)C=N2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(C)C=N2)CC1 BADUZVJYQXNZNK-FIWHBWSRSA-N 0.000 description 1
- QEKRAKNULUTDHB-YMBRHYMPSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(C)N=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(C)N=C2)CC1 QEKRAKNULUTDHB-YMBRHYMPSA-N 0.000 description 1
- XLAWPDHBBMNTEC-FKHAVUOCSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(CCC#N)N=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(CCC#N)N=C2)CC1 XLAWPDHBBMNTEC-FKHAVUOCSA-N 0.000 description 1
- CSOMYTSARQVEIH-PSDZMVHGSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(CCO)N=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CN(CCO)N=C2)CC1 CSOMYTSARQVEIH-PSDZMVHGSA-N 0.000 description 1
- LJTZIDBPBGQVNF-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=NN(C)C=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=NN(C)C=C2)CC1 LJTZIDBPBGQVNF-FIWHBWSRSA-N 0.000 description 1
- UFUVVQDCHPOQKA-ZMFCMNQTSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=NN(CCC#N)C=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=NN(CCC#N)C=C2)CC1 UFUVVQDCHPOQKA-ZMFCMNQTSA-N 0.000 description 1
- SYAPHHGIJLPFDW-VQCQRNETSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=NN(CCO)C=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=NN(CCO)C=C2)CC1 SYAPHHGIJLPFDW-VQCQRNETSA-N 0.000 description 1
- FFGZMSYMDSBJPK-WTQRLHSKSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2CCN(C)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2CCN(C)CC2)CC1 FFGZMSYMDSBJPK-WTQRLHSKSA-N 0.000 description 1
- KUSGRBSWVRASNP-QSVWIEALSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CC(O)C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CC(O)C2)CC1 KUSGRBSWVRASNP-QSVWIEALSA-N 0.000 description 1
- RSISIOKJDKJAOX-PSDZMVHGSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC(O)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC(O)CC2)CC1 RSISIOKJDKJAOX-PSDZMVHGSA-N 0.000 description 1
- UTLYVMBMOIJDRS-FKHAVUOCSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC(OC)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC(OC)CC2)CC1 UTLYVMBMOIJDRS-FKHAVUOCSA-N 0.000 description 1
- PFGSTEADLXVAMQ-JAZPPYFYSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC[C@@H](O)C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC[C@@H](O)C2)CC1 PFGSTEADLXVAMQ-JAZPPYFYSA-N 0.000 description 1
- PFGSTEADLXVAMQ-LKXRKSRJSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC[C@H](O)C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCC[C@H](O)C2)CC1 PFGSTEADLXVAMQ-LKXRKSRJSA-N 0.000 description 1
- GYXBWXKPUYZOKG-ZMFCMNQTSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCN(C)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CCN(C)CC2)CC1 GYXBWXKPUYZOKG-ZMFCMNQTSA-N 0.000 description 1
- CQGWIOXNCBPCIM-OSBQEZSISA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CC[C@@H](O)C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CC[C@@H](O)C2)CC1 CQGWIOXNCBPCIM-OSBQEZSISA-N 0.000 description 1
- CQGWIOXNCBPCIM-PDYHCXRVSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CC[C@H](O)C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)N2CC[C@H](O)C2)CC1 CQGWIOXNCBPCIM-PDYHCXRVSA-N 0.000 description 1
- PTPNRMQEOFVZGW-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 PTPNRMQEOFVZGW-FIWHBWSRSA-N 0.000 description 1
- LDKNFWWJNHSUAR-QFMSAKRMSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)[C@@H]2CCCN2C)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)[C@@H]2CCCN2C)CC1 LDKNFWWJNHSUAR-QFMSAKRMSA-N 0.000 description 1
- SCJPKXYMZGUAEC-IZDUKZDJSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)[C@H]2CC[C@@H](CO)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)[C@H]2CC[C@@H](CO)CC2)CC1 SCJPKXYMZGUAEC-IZDUKZDJSA-N 0.000 description 1
- SCJPKXYMZGUAEC-WEROFJHNSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)[C@H]2CC[C@H](CO)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)[C@H]2CC[C@H](CO)CC2)CC1 SCJPKXYMZGUAEC-WEROFJHNSA-N 0.000 description 1
- MELFWAQYYVHRBE-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 MELFWAQYYVHRBE-FIWHBWSRSA-N 0.000 description 1
- ZUZVSPUJQYYAIE-VQCQRNETSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 ZUZVSPUJQYYAIE-VQCQRNETSA-N 0.000 description 1
- WYOMNVYESIOVOC-ZMFCMNQTSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCCC2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCCC2)CC1 WYOMNVYESIOVOC-ZMFCMNQTSA-N 0.000 description 1
- VTYJHMLAKVWWTO-MIHMCVIASA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2=CC=C(C(=O)O)C=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2=CC=C(C(=O)O)C=C2)CC1 VTYJHMLAKVWWTO-MIHMCVIASA-N 0.000 description 1
- AYNOHMQSFLHRKF-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(S(=O)(=O)C2=CC=NN2C)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(S(=O)(=O)C2=CC=NN2C)CC1 AYNOHMQSFLHRKF-FIWHBWSRSA-N 0.000 description 1
- BYKHGWWCDWJCAF-YMBRHYMPSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(S(=O)(=O)C2=CN(C)N=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(S(=O)(=O)C2=CN(C)N=C2)CC1 BYKHGWWCDWJCAF-YMBRHYMPSA-N 0.000 description 1
- CNLJHRREGLBOFC-FIWHBWSRSA-N COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(S(=O)(=O)C2=NN(C)C=C2)CC1 Chemical compound COCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(S(=O)(=O)C2=NN(C)C=C2)CC1 CNLJHRREGLBOFC-FIWHBWSRSA-N 0.000 description 1
- NXIDYEZEYFPVCM-BPGUCPLFSA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CNN=C2)CC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)C2=CNN=C2)CC1 NXIDYEZEYFPVCM-BPGUCPLFSA-N 0.000 description 1
- COAQPEGGYWQKCR-BPGUCPLFSA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC(C)(C)C)CC1 COAQPEGGYWQKCR-BPGUCPLFSA-N 0.000 description 1
- NPRWPBNLZIUSMQ-XMMISQBUSA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC2=CC=CC=C2)CC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(C(=O)OC2=CC=CC=C2)CC1 NPRWPBNLZIUSMQ-XMMISQBUSA-N 0.000 description 1
- JHYAQGKVZAZERR-FXDYGKIASA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)OC(C)(C)C)CCCC2)CC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)OC(C)(C)C)CCCC2)CC1 JHYAQGKVZAZERR-FXDYGKIASA-N 0.000 description 1
- KKHPNWRUKNXXHZ-FOIFJWKZSA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)OC)CC2)CC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)OC)CC2)CC1 KKHPNWRUKNXXHZ-FOIFJWKZSA-N 0.000 description 1
- FOFKYXIWTJSOLF-OZAIVSQSSA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)OC)CCC2)CC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)OC)CCC2)CC1 FOFKYXIWTJSOLF-OZAIVSQSSA-N 0.000 description 1
- VIKCEFPWNAPNJE-QRWMCTBCSA-N COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCNCC1 Chemical compound COCC1(CN(C(C)=O)[C@@H]2CC2C2=CC=CC=C2)CCNCC1 VIKCEFPWNAPNJE-QRWMCTBCSA-N 0.000 description 1
- FAABVQIBIYGNJV-UHFFFAOYSA-N COCC1(CO)CCCCC1 Chemical compound COCC1(CO)CCCCC1 FAABVQIBIYGNJV-UHFFFAOYSA-N 0.000 description 1
- CHWHIXFEOMHDCT-UHFFFAOYSA-N COCC1(CO)CCN(CC2(C(=O)OC)CCC2)CC1 Chemical compound COCC1(CO)CCN(CC2(C(=O)OC)CCC2)CC1 CHWHIXFEOMHDCT-UHFFFAOYSA-N 0.000 description 1
- ZXSAHAQADJAIET-FKHAVUOCSA-N COCCN1C=C(C(=O)N2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC)CC2)C=N1 Chemical compound COCCN1C=C(C(=O)N2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC)CC2)C=N1 ZXSAHAQADJAIET-FKHAVUOCSA-N 0.000 description 1
- PCVXWPWCLWTOSR-TZMCWYRMSA-N C[C@H](C1)[C@@H]1NCC(COC)(CC1)CCN1C(c1ccc(N)nn1)=O Chemical compound C[C@H](C1)[C@@H]1NCC(COC)(CC1)CCN1C(c1ccc(N)nn1)=O PCVXWPWCLWTOSR-TZMCWYRMSA-N 0.000 description 1
- XPKDUIRFYQOIBN-UKRRQHHQSA-N C[C@H](C1)[C@@H]1NCC(COC)(CC1)CCN1C(c1n[n](C)cc1)=O Chemical compound C[C@H](C1)[C@@H]1NCC(COC)(CC1)CCN1C(c1n[n](C)cc1)=O XPKDUIRFYQOIBN-UKRRQHHQSA-N 0.000 description 1
- OOPCHSQNOIQBFX-NVXWUHKLSA-N C[C@H](C1)[C@@H]1NCC(COC)(CC1)CCN1C(c1n[n](CCC#N)cc1)=O Chemical compound C[C@H](C1)[C@@H]1NCC(COC)(CC1)CCN1C(c1n[n](CCC#N)cc1)=O OOPCHSQNOIQBFX-NVXWUHKLSA-N 0.000 description 1
- PLOTYZGDHRMQBV-JHMKDJTOSA-N C[C@H](C1)[C@@H]1NCC(Cc(cc1)ccc1F)(CC1)CCN1C([C@H](CC1)CC[C@@H]1N)=O Chemical compound C[C@H](C1)[C@@H]1NCC(Cc(cc1)ccc1F)(CC1)CCN1C([C@H](CC1)CC[C@@H]1N)=O PLOTYZGDHRMQBV-JHMKDJTOSA-N 0.000 description 1
- PQBCYZNFMVQUKJ-IEBWSBKVSA-N C[C@H](C1)[C@@H]1NCC1(COCC2CCC2)CCN(CC2(CCC2)C(O)=O)CC1 Chemical compound C[C@H](C1)[C@@H]1NCC1(COCC2CCC2)CCN(CC2(CCC2)C(O)=O)CC1 PQBCYZNFMVQUKJ-IEBWSBKVSA-N 0.000 description 1
- BLGJTYLSEPHCBV-UHFFFAOYSA-N FC1=CC=C(CN2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 Chemical compound FC1=CC=C(CN2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 BLGJTYLSEPHCBV-UHFFFAOYSA-N 0.000 description 1
- FVBDANOEPDIEAQ-UHFFFAOYSA-N FC1=CC=C(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)C=C1 Chemical compound FC1=CC=C(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)C=C1 FVBDANOEPDIEAQ-UHFFFAOYSA-N 0.000 description 1
- RATNURYVYUSCTF-UHFFFAOYSA-N N#CC1(C2=CC=CC=C2)CCN(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)CC1 Chemical compound N#CC1(C2=CC=CC=C2)CCN(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)CC1 RATNURYVYUSCTF-UHFFFAOYSA-N 0.000 description 1
- MHZXYDQDZUMZRK-DCWQJPKNSA-N N#CC1=CC(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)=CC=C1 Chemical compound N#CC1=CC(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)=CC=C1 MHZXYDQDZUMZRK-DCWQJPKNSA-N 0.000 description 1
- YAYPCJXYQYMQID-AVJYQCBHSA-N N#CC1=CC(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)=CC=C1 Chemical compound N#CC1=CC(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)=CC=C1 YAYPCJXYQYMQID-AVJYQCBHSA-N 0.000 description 1
- GPQVGFKYUQTOIU-XQZUBTRRSA-N N#CC1=CC(F)=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 Chemical compound N#CC1=CC(F)=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 GPQVGFKYUQTOIU-XQZUBTRRSA-N 0.000 description 1
- NNJULZOTGNXDCI-RMVMEJTISA-N N#CC1=CC(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)=CC=C1 Chemical compound N#CC1=CC(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)=CC=C1 NNJULZOTGNXDCI-RMVMEJTISA-N 0.000 description 1
- VXEIXGHJLXHWKU-CSMDKSQMSA-N N#CC1=CC(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)=CC=C1 Chemical compound N#CC1=CC(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)=CC=C1 VXEIXGHJLXHWKU-CSMDKSQMSA-N 0.000 description 1
- KKJFIBNFYKOCOT-UHFFFAOYSA-N N#CC1=CC=C(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 Chemical compound N#CC1=CC=C(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 KKJFIBNFYKOCOT-UHFFFAOYSA-N 0.000 description 1
- JGNZDYQPQBQOFK-DCWQJPKNSA-N N#CC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 Chemical compound N#CC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 JGNZDYQPQBQOFK-DCWQJPKNSA-N 0.000 description 1
- SYZFTLZBPLKZCV-UHFFFAOYSA-N N#CC1=CC=C(CN2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 Chemical compound N#CC1=CC=C(CN2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 SYZFTLZBPLKZCV-UHFFFAOYSA-N 0.000 description 1
- OOVKJZWKTDBFTA-MIHMCVIASA-N N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C(F)=C1 Chemical compound N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C(F)=C1 OOVKJZWKTDBFTA-MIHMCVIASA-N 0.000 description 1
- GZLFHGBHNGDINP-RMVMEJTISA-N N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 Chemical compound N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 GZLFHGBHNGDINP-RMVMEJTISA-N 0.000 description 1
- LTKGAFJBACYPCZ-IKOFQBKESA-N N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C(F)=C1 Chemical compound N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C(F)=C1 LTKGAFJBACYPCZ-IKOFQBKESA-N 0.000 description 1
- RHGOOAKJAJCRIA-CSMDKSQMSA-N N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C=C1 Chemical compound N#CC1=CC=C(OCC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C=C1 RHGOOAKJAJCRIA-CSMDKSQMSA-N 0.000 description 1
- CDGXNYWNBCWSJD-UHFFFAOYSA-N N#CC1=CC=CC(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 Chemical compound N#CC1=CC=CC(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 CDGXNYWNBCWSJD-UHFFFAOYSA-N 0.000 description 1
- KNQUCWZHSLFAFE-BULBDLIISA-N N#CC1=CC=CC(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(C[C@H]3CC[C@H](C(=O)O)CC3)CC2)=C1 Chemical compound N#CC1=CC=CC(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(C[C@H]3CC[C@H](C(=O)O)CC3)CC2)=C1 KNQUCWZHSLFAFE-BULBDLIISA-N 0.000 description 1
- DDPHYXNMBISXEG-UHFFFAOYSA-N N#CC1=CC=CC(CN2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 Chemical compound N#CC1=CC=CC(CN2CC(CCC3CC3C3=CC=CC=C3)C2)=C1 DDPHYXNMBISXEG-UHFFFAOYSA-N 0.000 description 1
- KIQQJLRXKCJSQV-XQZUBTRRSA-N N#CC1=CC=CC=C1OCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 Chemical compound N#CC1=CC=CC=C1OCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CC2)CC1 KIQQJLRXKCJSQV-XQZUBTRRSA-N 0.000 description 1
- JJNQLKRMKXTUDQ-RMVMEJTISA-N N#CC1=CC=CC=C1OCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 Chemical compound N#CC1=CC=CC=C1OCC1(CC[C@@H]2CC2C2=CC=CC=C2)CCN(CC2(C(=O)O)CCC2)CC1 JJNQLKRMKXTUDQ-RMVMEJTISA-N 0.000 description 1
- ZCZFIHXXXYYOCB-UHFFFAOYSA-N N#CC1CCN(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)CC1 Chemical compound N#CC1CCN(C(=O)N2CC(CCC3CC3C3=CC=CC=C3)C2)CC1 ZCZFIHXXXYYOCB-UHFFFAOYSA-N 0.000 description 1
- PQGVUBSQANNHGG-UHFFFAOYSA-N N#CCC1(CCC2CC2C2=CC=CC=C2)CCN(C(=O)C2=CC=CC(F)=C2)CC1 Chemical compound N#CCC1(CCC2CC2C2=CC=CC=C2)CCN(C(=O)C2=CC=CC(F)=C2)CC1 PQGVUBSQANNHGG-UHFFFAOYSA-N 0.000 description 1
- CIZSWZQJQJBEMV-UHFFFAOYSA-N N#CCC1(CCC2CC2C2=CC=CC=C2)CCN(CC2=CC=CC(F)=C2)CC1 Chemical compound N#CCC1(CCC2CC2C2=CC=CC=C2)CCN(CC2=CC=CC(F)=C2)CC1 CIZSWZQJQJBEMV-UHFFFAOYSA-N 0.000 description 1
- ATKPSLQYRMLCNM-UHFFFAOYSA-N N#CCC1(CN(C(=O)C(F)(F)F)C2CC2C2=CC=CC=C2)CCNCC1 Chemical compound N#CCC1(CN(C(=O)C(F)(F)F)C2CC2C2=CC=CC=C2)CCNCC1 ATKPSLQYRMLCNM-UHFFFAOYSA-N 0.000 description 1
- XNWUVFUHDNSHDZ-AVJYQCBHSA-N N#CCC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 Chemical compound N#CCC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CC3)CC2)C=C1 XNWUVFUHDNSHDZ-AVJYQCBHSA-N 0.000 description 1
- VORXBJSODCAUJM-QXPUDEPPSA-N N#CCC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C=C1 Chemical compound N#CCC1=CC=C(CC2(CC[C@@H]3CC3C3=CC=CC=C3)CCN(CC3(C(=O)O)CCC3)CC2)C=C1 VORXBJSODCAUJM-QXPUDEPPSA-N 0.000 description 1
- XBFXRPMWRSDXAO-XQZUBTRRSA-N NC1(C(=O)N2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CCC1 Chemical compound NC1(C(=O)N2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CCC1 XBFXRPMWRSDXAO-XQZUBTRRSA-N 0.000 description 1
- PWPJZAQGRCZCIZ-UHFFFAOYSA-N NCC1(Cc(cc2)ccc2F)CCN(CC2(CC2)C(O)=O)CC1 Chemical compound NCC1(Cc(cc2)ccc2F)CCN(CC2(CC2)C(O)=O)CC1 PWPJZAQGRCZCIZ-UHFFFAOYSA-N 0.000 description 1
- QHDAGTHONNVPDJ-AUTNKXAOSA-N N[C@H]1CC[C@H](C(=O)N2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CC1 Chemical compound N[C@H]1CC[C@H](C(=O)N2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CC1 QHDAGTHONNVPDJ-AUTNKXAOSA-N 0.000 description 1
- TYQFQZSEBMXQGW-UHFFFAOYSA-N O=C(C(F)(F)F)N(CC1CNC1)C(C1)C1c1ccccc1 Chemical compound O=C(C(F)(F)F)N(CC1CNC1)C(C1)C1c1ccccc1 TYQFQZSEBMXQGW-UHFFFAOYSA-N 0.000 description 1
- XOBRTBLCHMAVPT-UHFFFAOYSA-N O=C(C1=CC(F)=CC=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(C1=CC(F)=CC=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 XOBRTBLCHMAVPT-UHFFFAOYSA-N 0.000 description 1
- FEQUBBIJBUWIQM-UHFFFAOYSA-N O=C(C1=CC=C(F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(C1=CC=C(F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 FEQUBBIJBUWIQM-UHFFFAOYSA-N 0.000 description 1
- IVLSGSIKQBADSY-UHFFFAOYSA-N O=C(N1CC(CCC2CC2C2=CC=CC=C2)C1)N1CCCC(OC2=CC=CC=C2)C1 Chemical compound O=C(N1CC(CCC2CC2C2=CC=CC=C2)C1)N1CCCC(OC2=CC=CC=C2)C1 IVLSGSIKQBADSY-UHFFFAOYSA-N 0.000 description 1
- ZCOYKAKDTAKZHX-VBTAHXNJSA-N O=C(N1CC(CCC2CC2C2=CC=CC=C2)C1)N1CCC[C@@]2(CCN(C3CCC(O)CC3)C2=O)C1 Chemical compound O=C(N1CC(CCC2CC2C2=CC=CC=C2)C1)N1CCC[C@@]2(CCN(C3CCC(O)CC3)C2=O)C1 ZCOYKAKDTAKZHX-VBTAHXNJSA-N 0.000 description 1
- ZCOYKAKDTAKZHX-PADIXYOTSA-N O=C(N1CC(CCC2CC2C2=CC=CC=C2)C1)N1CCC[C@]2(CCN(C3CCC(O)CC3)C2=O)C1 Chemical compound O=C(N1CC(CCC2CC2C2=CC=CC=C2)C1)N1CCC[C@]2(CCN(C3CCC(O)CC3)C2=O)C1 ZCOYKAKDTAKZHX-PADIXYOTSA-N 0.000 description 1
- XGXMFVLNWNZEOJ-UHFFFAOYSA-N O=C(N1CCC(C(F)(F)F)CC1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(N1CCC(C(F)(F)F)CC1)N1CC(CCC2CC2C2=CC=CC=C2)C1 XGXMFVLNWNZEOJ-UHFFFAOYSA-N 0.000 description 1
- UODZTHQVRNGSEQ-UHFFFAOYSA-N O=C(N1CCC(O)(C2=CC=CC=C2)CC1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(N1CCC(O)(C2=CC=CC=C2)CC1)N1CC(CCC2CC2C2=CC=CC=C2)C1 UODZTHQVRNGSEQ-UHFFFAOYSA-N 0.000 description 1
- RIZHHCJQHDJTCD-UHFFFAOYSA-N O=C(N1CCC2(CC1)CNC1=C2C=C(F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(N1CCC2(CC1)CNC1=C2C=C(F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 RIZHHCJQHDJTCD-UHFFFAOYSA-N 0.000 description 1
- LOMKRLZXHMQDFL-UHFFFAOYSA-N O=C(NC1=C(F)C=CC=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(NC1=C(F)C=CC=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 LOMKRLZXHMQDFL-UHFFFAOYSA-N 0.000 description 1
- UVOJLFBKSYDCDF-UHFFFAOYSA-N O=C(NC1=CC(F)=CC=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(NC1=CC(F)=CC=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 UVOJLFBKSYDCDF-UHFFFAOYSA-N 0.000 description 1
- HHSSAPWOSHGJRO-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=C(NC1=CC=C(F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 HHSSAPWOSHGJRO-UHFFFAOYSA-N 0.000 description 1
- RWXCDFRDZLKBCS-XQZUBTRRSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CC1 RWXCDFRDZLKBCS-XQZUBTRRSA-N 0.000 description 1
- DYSOFLQMALKJPE-RMVMEJTISA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=CC=C(F)C=C3)CC2)CCC1 DYSOFLQMALKJPE-RMVMEJTISA-N 0.000 description 1
- ZUDPNKDWSMKHCN-CILPGNKCSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=NC=C(F)C=C3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=NC=C(F)C=C3)CC2)CC1 ZUDPNKDWSMKHCN-CILPGNKCSA-N 0.000 description 1
- IMHSABCEFLPJJP-UFUCKMQHSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=NC=C(F)C=C3)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(CC3=NC=C(F)C=C3)CC2)CCC1 IMHSABCEFLPJJP-UFUCKMQHSA-N 0.000 description 1
- DYWFZUDJMBYPRS-ZMFCMNQTSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=C(F)C=CC=N3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=C(F)C=CC=N3)CC2)CC1 DYWFZUDJMBYPRS-ZMFCMNQTSA-N 0.000 description 1
- DSEVYRQRGYQJOA-FKHAVUOCSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=C(F)C=N3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=C(F)C=N3)CC2)CC1 DSEVYRQRGYQJOA-FKHAVUOCSA-N 0.000 description 1
- RGGZIPPIIYVQIO-UFUCKMQHSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC(F)=C3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC(F)=C3)CC2)CC1 RGGZIPPIIYVQIO-UFUCKMQHSA-N 0.000 description 1
- DUVAUUUSTPAITJ-GEPVFLLWSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC(F)=C3)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC(F)=C3)CC2)CCC1 DUVAUUUSTPAITJ-GEPVFLLWSA-N 0.000 description 1
- JTFZXGNVEVQELO-WTQRLHSKSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC=C3F)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC=C3F)CC2)CC1 JTFZXGNVEVQELO-WTQRLHSKSA-N 0.000 description 1
- ZBXCDNQMCYQAII-MIHMCVIASA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC=C3F)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=CC=CC=C3F)CC2)CCC1 ZBXCDNQMCYQAII-MIHMCVIASA-N 0.000 description 1
- TVPLQQHLJYPWIT-PSDZMVHGSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=NC=C(F)C=N3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3=NC=C(F)C=N3)CC2)CC1 TVPLQQHLJYPWIT-PSDZMVHGSA-N 0.000 description 1
- HPUGPEFAMNBDHY-XQZUBTRRSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3CCCCC3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3CCCCC3)CC2)CC1 HPUGPEFAMNBDHY-XQZUBTRRSA-N 0.000 description 1
- IFQYZSCFXUZKNE-RMVMEJTISA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3CCCCC3)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COC3CCCCC3)CC2)CCC1 IFQYZSCFXUZKNE-RMVMEJTISA-N 0.000 description 1
- XIMIYEJLQZVQCK-DCWQJPKNSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3=CC=CC=C3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3=CC=CC=C3)CC2)CC1 XIMIYEJLQZVQCK-DCWQJPKNSA-N 0.000 description 1
- AGTFIDXCJPNQPQ-AVJYQCBHSA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3=CC=CC=C3)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3=CC=CC=C3)CC2)CCC1 AGTFIDXCJPNQPQ-AVJYQCBHSA-N 0.000 description 1
- NJKRIUBNDUXBRW-MIHMCVIASA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3CCC3)CC2)CC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3CCC3)CC2)CC1 NJKRIUBNDUXBRW-MIHMCVIASA-N 0.000 description 1
- IMLYNRFCLHOIDM-IKOFQBKESA-N O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3CCC3)CC2)CCC1 Chemical compound O=C(O)C1(CN2CCC(CC[C@@H]3CC3C3=CC=CC=C3)(COCC3CCC3)CC2)CCC1 IMLYNRFCLHOIDM-IKOFQBKESA-N 0.000 description 1
- MRKGREXESIOGRS-UHFFFAOYSA-N O=C(O)C1=CC(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)=CC=C1 Chemical compound O=C(O)C1=CC(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)=CC=C1 MRKGREXESIOGRS-UHFFFAOYSA-N 0.000 description 1
- QMSSLYTXJDLPHM-UHFFFAOYSA-N O=C(O)C1=CC=C(CN2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 Chemical compound O=C(O)C1=CC=C(CN2CC(CCC3CC3C3=CC=CC=C3)C2)C=C1 QMSSLYTXJDLPHM-UHFFFAOYSA-N 0.000 description 1
- JWADYQPSSHTBCD-UHFFFAOYSA-N O=C(O)C1=CC=C(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)C=C1 Chemical compound O=C(O)C1=CC=C(CN2CCC(CC3CC3C3=CC=CC=C3)CC2)C=C1 JWADYQPSSHTBCD-UHFFFAOYSA-N 0.000 description 1
- QMNAGGZINCOGFS-UHFFFAOYSA-N O=S(=O)(C1=CC=C(OC(F)(F)F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 Chemical compound O=S(=O)(C1=CC=C(OC(F)(F)F)C=C1)N1CC(CCC2CC2C2=CC=CC=C2)C1 QMNAGGZINCOGFS-UHFFFAOYSA-N 0.000 description 1
- GXEBZZCIQAQLMQ-WUBHUQEYSA-N OC(C1(CN2CCC(CN[C@H](C3)C3c3ccccc3)(COCc3ccccc3)CC2)CC1)=O Chemical compound OC(C1(CN2CCC(CN[C@H](C3)C3c3ccccc3)(COCc3ccccc3)CC2)CC1)=O GXEBZZCIQAQLMQ-WUBHUQEYSA-N 0.000 description 1
- PLTNJEKWZXMTQE-UHFFFAOYSA-N [C-]#[N+]CC1=CC=C(CC2(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC2)C=C1 Chemical compound [C-]#[N+]CC1=CC=C(CC2(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC2)C=C1 PLTNJEKWZXMTQE-UHFFFAOYSA-N 0.000 description 1
- KCBCPTPXLCZREQ-UHFFFAOYSA-N [C-]#[N+]CC1=CC=C(CC2(C=O)CCN(C(=O)OC(C)(C)C)CC2)C=C1 Chemical compound [C-]#[N+]CC1=CC=C(CC2(C=O)CCN(C(=O)OC(C)(C)C)CC2)C=C1 KCBCPTPXLCZREQ-UHFFFAOYSA-N 0.000 description 1
- GGJQYVUSIYEADV-UHFFFAOYSA-N [C-]#[N+]CC1=CC=C(CC2(CO)CCN(C(=O)OC(C)(C)C)CC2)C=C1 Chemical compound [C-]#[N+]CC1=CC=C(CC2(CO)CCN(C(=O)OC(C)(C)C)CC2)C=C1 GGJQYVUSIYEADV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/620,903 US9670210B2 (en) | 2014-02-13 | 2015-02-12 | Cyclopropylamines as LSD1 inhibitors |
US15/497,887 US10174030B2 (en) | 2014-02-13 | 2017-04-26 | Cyclopropylamines as LSD1 inhibitors |
US16/195,026 US10717737B2 (en) | 2014-02-13 | 2018-11-19 | Cyclopropylamines as LSD1 inhibitors |
US16/897,051 US11247992B2 (en) | 2014-02-13 | 2020-06-09 | Cyclopropylamines as LSD1 inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461939488P | 2014-02-13 | 2014-02-13 | |
US201462061283P | 2014-10-08 | 2014-10-08 | |
US14/620,903 US9670210B2 (en) | 2014-02-13 | 2015-02-12 | Cyclopropylamines as LSD1 inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/497,887 Continuation US10174030B2 (en) | 2014-02-13 | 2017-04-26 | Cyclopropylamines as LSD1 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150225401A1 US20150225401A1 (en) | 2015-08-13 |
US9670210B2 true US9670210B2 (en) | 2017-06-06 |
Family
ID=52589819
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/620,903 Active US9670210B2 (en) | 2014-02-13 | 2015-02-12 | Cyclopropylamines as LSD1 inhibitors |
US15/497,887 Active US10174030B2 (en) | 2014-02-13 | 2017-04-26 | Cyclopropylamines as LSD1 inhibitors |
US16/195,026 Active US10717737B2 (en) | 2014-02-13 | 2018-11-19 | Cyclopropylamines as LSD1 inhibitors |
US16/897,051 Active US11247992B2 (en) | 2014-02-13 | 2020-06-09 | Cyclopropylamines as LSD1 inhibitors |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/497,887 Active US10174030B2 (en) | 2014-02-13 | 2017-04-26 | Cyclopropylamines as LSD1 inhibitors |
US16/195,026 Active US10717737B2 (en) | 2014-02-13 | 2018-11-19 | Cyclopropylamines as LSD1 inhibitors |
US16/897,051 Active US11247992B2 (en) | 2014-02-13 | 2020-06-09 | Cyclopropylamines as LSD1 inhibitors |
Country Status (31)
Country | Link |
---|---|
US (4) | US9670210B2 (ja) |
EP (2) | EP3105218B1 (ja) |
JP (2) | JP6602778B2 (ja) |
KR (1) | KR102421235B1 (ja) |
CN (2) | CN106164066B (ja) |
AU (2) | AU2015217073B2 (ja) |
CA (1) | CA2939082C (ja) |
CL (1) | CL2016002027A1 (ja) |
CR (2) | CR20200199A (ja) |
CY (1) | CY1122415T1 (ja) |
DK (1) | DK3105218T3 (ja) |
EC (1) | ECSP16073190A (ja) |
ES (2) | ES2901711T3 (ja) |
HR (1) | HRP20192167T1 (ja) |
HU (1) | HUE046273T2 (ja) |
IL (2) | IL247134B (ja) |
LT (1) | LT3105218T (ja) |
ME (1) | ME03654B (ja) |
MX (2) | MX2016010395A (ja) |
MY (1) | MY183499A (ja) |
PE (1) | PE20161573A1 (ja) |
PH (1) | PH12016501601A1 (ja) |
PL (1) | PL3105218T3 (ja) |
PT (1) | PT3105218T (ja) |
RS (1) | RS59559B1 (ja) |
SG (3) | SG10201908028SA (ja) |
SI (1) | SI3105218T1 (ja) |
TW (2) | TWI685483B (ja) |
UA (1) | UA126541C2 (ja) |
WO (1) | WO2015123465A1 (ja) |
ZA (1) | ZA201606275B (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9994546B2 (en) | 2014-02-13 | 2018-06-12 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10047086B2 (en) | 2014-07-10 | 2018-08-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as LSD1 inhibitors |
US10112950B2 (en) | 2014-07-10 | 2018-10-30 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US10125133B2 (en) | 2014-07-10 | 2018-11-13 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US10138249B2 (en) | 2014-07-10 | 2018-11-27 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
US10174030B2 (en) | 2014-02-13 | 2019-01-08 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10300051B2 (en) | 2014-02-13 | 2019-05-28 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
US10513493B2 (en) | 2014-02-13 | 2019-12-24 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10800779B2 (en) | 2015-04-03 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
KR102626978B1 (ko) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | 질환 치료를 위한 kdm1a 저해제 |
EP3307909A1 (en) | 2015-06-12 | 2018-04-18 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
KR20180117602A (ko) | 2015-12-29 | 2018-10-29 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
CN107200706A (zh) * | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
EP3430015A1 (en) | 2016-03-16 | 2019-01-23 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
KR102479789B1 (ko) * | 2016-05-09 | 2022-12-22 | 주빌런트 에피코어 엘엘씨 | 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물 |
CN107459476B (zh) * | 2016-06-03 | 2022-06-24 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
CN111194306B (zh) * | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
CA3056527A1 (en) | 2017-01-24 | 2018-08-02 | Medshine Discovery Inc. | Lsd1 inhibitor and preparation method and application thereof |
CN106860453A (zh) * | 2017-02-17 | 2017-06-20 | 杨燕 | 一种治疗溃疡性结肠炎的药物组合物 |
US11168082B2 (en) | 2017-05-15 | 2021-11-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors |
CN110996949A (zh) | 2017-08-03 | 2020-04-10 | 奥瑞泽恩基因组学股份有限公司 | 用于治疗行为改变的方法 |
US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
KR20210008064A (ko) | 2018-05-11 | 2021-01-20 | 이마고 바이오사이언시즈 인코포레이티드 | 질환의 치료를 위한 kdm1a 저해제 |
CN112119080B (zh) | 2018-05-15 | 2023-07-11 | 密歇根大学董事会 | 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CA3130638A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
WO2021058024A1 (zh) * | 2019-09-29 | 2021-04-01 | 南京明德新药研发有限公司 | Lsd1抑制剂 |
KR20230004724A (ko) * | 2020-04-21 | 2023-01-06 | 아이디언스 주식회사 | 프탈라지논 유도체 및 이의 중간체의 제조 방법 |
EP4319732A1 (en) | 2021-04-08 | 2024-02-14 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
WO2023067058A1 (en) | 2021-10-20 | 2023-04-27 | Queen Mary University Of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
GB202115017D0 (en) | 2021-10-20 | 2021-12-01 | Univ London Queen Mary | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
Citations (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988004298A1 (en) | 1986-12-05 | 1988-06-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 8-alkylaminoimidazo[1,2-a]pyrazines and derivatives, their preparation and their application in therapy |
EP0404190A1 (en) | 1989-06-23 | 1990-12-27 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
EP0430385A2 (en) | 1989-11-30 | 1991-06-05 | Schering Aktiengesellschaft | Substituted 1,2,4-triazolo-[4,3-a]pyridines, and substituted N'-(2-pyridyl)-hydrazones, and their use as herbicides |
FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
WO1993025553A1 (en) | 1992-06-17 | 1993-12-23 | The Upjohn Company | Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents |
WO1994018198A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Aktiengesellschaft | Imidazoazine |
WO1995012594A1 (fr) | 1993-11-05 | 1995-05-11 | Rhone-Poulenc Rorer S.A. | 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE ANTAGONISTES DU RECEPTEUR NMDA |
WO1999024434A1 (en) | 1997-11-11 | 1999-05-20 | Ono Pharmaceutical Co., Ltd. | Fused pyrazine compounds |
JP2000319278A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP2001006877A (ja) | 1999-06-21 | 2001-01-12 | Toray Ind Inc | 発光素子 |
JP2001035664A (ja) | 1999-07-21 | 2001-02-09 | Mitsui Chemicals Inc | 有機電界発光素子 |
JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
WO2001027119A2 (de) | 1999-10-08 | 2001-04-19 | Grünenthal GmbH | Substanzbibliothek enthaltend bicyclische imidazo-5-yl-amine und/oder bicyclische imidazo-3-yl-amine |
JP2001114780A (ja) | 1999-10-18 | 2001-04-24 | Yakult Honsha Co Ltd | 三環性縮合イミダゾール誘導体 |
WO2001083481A1 (fr) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'imidazopyridine |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
WO2002034748A1 (en) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Imidazopyridine derivatives |
WO2002038562A1 (fr) | 2000-11-08 | 2002-05-16 | Sumitomo Chemical Takeda Agro Company, Limited | Derives de triazolone bicycliques et herbicides contenant ces derniers |
WO2002051831A1 (en) | 2000-12-23 | 2002-07-04 | Aventis Pharma Deutschland Gmbh | Oxybenzamides derivatives as factor xa inhibitors |
WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
US20020151549A1 (en) | 2000-04-27 | 2002-10-17 | Masahiko Hayakawa | Imidazopyridine derivatives |
WO2003006471A1 (en) | 2001-07-13 | 2003-01-23 | Neurogen Corporation | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
WO2003044021A2 (en) | 2001-11-16 | 2003-05-30 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
WO2003062392A2 (en) | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
US20040023972A1 (en) | 2000-10-13 | 2004-02-05 | Gruenenthal Gmbh | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
WO2004021989A2 (en) | 2002-09-06 | 2004-03-18 | Biogen Idec Ma Inc. | Imidazolopyridines and methods of making and using the same |
US20040058938A1 (en) | 2000-12-13 | 2004-03-25 | Oliver Cullmann | Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds |
US20040082635A1 (en) | 2001-06-26 | 2004-04-29 | Hiromasa Hashimoto | Fused cyclic compounds and medicinal use thereof |
US20040082781A1 (en) | 2001-02-08 | 2004-04-29 | Shigeki Hibi | Bicyclic nitrogenous fused-ring compound |
WO2004058762A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2004074290A1 (en) | 2003-02-20 | 2004-09-02 | Merck Sharp & Dohme Limited | Substituted amino heterocycles as vr-1 antagonists for treating pain |
WO2004089380A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of fused 1,2,4-triazoles |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
US20040220189A1 (en) | 2003-02-20 | 2004-11-04 | Sugen, Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors |
WO2004096131A2 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2004108692A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) |
US20050009832A1 (en) | 2003-02-20 | 2005-01-13 | Sugen, Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
WO2005007658A2 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2005025558A1 (en) | 2003-09-12 | 2005-03-24 | Applied Reserach Systems Ars Holding N.V. | Sulfonamide derivatives for the treatment of diabetes |
JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
WO2005035532A1 (en) | 2003-10-10 | 2005-04-21 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
WO2005042537A1 (en) | 2003-10-22 | 2005-05-12 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
WO2005044793A2 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
WO2005097052A1 (en) | 2004-03-30 | 2005-10-20 | The Procter & Gamble Company | Keratin dyeing compositions bicyclic 5-6 heteroaromatic dyeing compounds with one ring nitrogen junction |
WO2006015263A2 (en) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
WO2006018727A2 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds useful for the treatment of inflammation |
WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
WO2006057946A2 (en) | 2004-11-22 | 2006-06-01 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer agents and prodrugs thereof |
WO2006058752A1 (en) | 2004-12-01 | 2006-06-08 | Laboratoires Serono S.A. | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
WO2006074041A2 (en) | 2004-12-31 | 2006-07-13 | National Health Research Institutes | Anti-tumor compounds |
WO2006073938A2 (en) | 2004-12-30 | 2006-07-13 | East Carolina University | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
US20060178399A1 (en) | 2003-03-14 | 2006-08-10 | Rena Nishizawa | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
US20060194842A1 (en) | 2005-02-22 | 2006-08-31 | Chikara Uchida | Oxyindole derivatives |
WO2006113704A2 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
WO2006131003A1 (en) | 2005-06-09 | 2006-12-14 | Oncalis Ag | Angiogenesis inhibitors |
WO2006135795A1 (en) | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006135667A1 (en) | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidiazo -and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006138734A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
WO2006138657A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
WO2006138695A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
WO2007022529A2 (en) | 2005-08-19 | 2007-02-22 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2007028051A2 (en) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
WO2007058942A2 (en) | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2007074491A1 (en) | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
US20070191395A1 (en) | 2004-02-16 | 2007-08-16 | Katsuhiro Kawakami | Heterocyclic compounds having antifungal activity |
WO2007095588A1 (en) | 2006-02-14 | 2007-08-23 | Novartis Ag | Pi-3 kinase inhibitors and methods of their use |
WO2007113226A1 (en) | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
WO2007145921A1 (en) | 2006-06-06 | 2007-12-21 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2007149478A2 (en) | 2006-06-22 | 2007-12-27 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
WO2008005262A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
WO2008005908A2 (en) | 2006-07-07 | 2008-01-10 | Forest Laboratories Holdings Limited | Pyridoimidazole derivatives |
WO2008005423A1 (en) | 2006-07-03 | 2008-01-10 | Cambrex Charles City, Inc. | Improved method of making sufentanil |
WO2008008539A2 (en) | 2006-07-14 | 2008-01-17 | Amgen Inc. | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
WO2008011560A2 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
DE102006041292A1 (de) | 2006-09-01 | 2008-03-06 | Henkel Kgaa | Wasserstoffperoxid-Aktivierung mit N-Heterocyclen |
WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
WO2008045393A2 (en) | 2006-10-11 | 2008-04-17 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use therof |
WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
WO2008064157A1 (en) | 2006-11-22 | 2008-05-29 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
WO2008065198A1 (en) | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
WO2008113559A2 (en) | 2007-03-21 | 2008-09-25 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as cns active compounds |
US20080249154A1 (en) | 2003-12-26 | 2008-10-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates |
WO2008125111A1 (en) | 2007-04-16 | 2008-10-23 | Leo Pharma A/S | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
WO2008141239A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
WO2008154241A1 (en) | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
US7468375B2 (en) * | 2004-04-26 | 2008-12-23 | Pfizer Inc. | Inhibitors of the HIV integrase enzyme |
WO2008157752A1 (en) | 2007-06-21 | 2008-12-24 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
WO2008156614A2 (en) | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2009010530A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
WO2009017701A2 (en) | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
FR2920091A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier. |
FR2920090A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier. |
WO2009045753A1 (en) | 2007-10-01 | 2009-04-09 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
WO2009047563A1 (en) | 2007-10-11 | 2009-04-16 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
WO2009047514A1 (en) | 2007-10-10 | 2009-04-16 | Cancer Research Technology Limited | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
WO2009085980A1 (en) | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents |
WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
WO2009091374A2 (en) | 2008-01-15 | 2009-07-23 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
US20090203690A1 (en) | 2007-06-08 | 2009-08-13 | Abbott Laboratories | 5-substituted indazoles as kinase inhibitors |
WO2009114180A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
WO2009114512A1 (en) | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
WO2009128520A1 (ja) | 2008-04-18 | 2009-10-22 | 塩野義製薬株式会社 | P13k阻害活性を有する複素環化合物 |
US20090318436A1 (en) | 2006-07-14 | 2009-12-24 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010019899A1 (en) | 2008-08-14 | 2010-02-18 | Takeda Pharmaceutical Company Limited | cMET INHIBITORS |
WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
JP2010070503A (ja) | 2008-09-19 | 2010-04-02 | Daiichi Sankyo Co Ltd | 抗真菌作用2−アミノトリアゾロピリジン誘導体 |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
US20100113441A1 (en) | 2007-03-16 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazopyrimidines and triazolopyrimidines |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
WO2010088368A2 (en) | 2009-01-29 | 2010-08-05 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2010091067A2 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2010104306A2 (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
WO2010108059A1 (en) | 2009-03-20 | 2010-09-23 | Incyte Corporation | Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor |
WO2010113942A1 (ja) | 2009-03-31 | 2010-10-07 | キッセイ薬品工業株式会社 | インドリジン誘導体及びその医薬用途 |
WO2010119264A1 (en) | 2009-04-16 | 2010-10-21 | Centro Nacional De Investigaciones Oncólogicas (Cnio) | Imidazopyrazines for use as kinase inhibitors |
WO2010136438A1 (en) | 2009-05-27 | 2010-12-02 | N.V. Organon | (dihydro) imidazoiso (5, 1-a) quinolines as fsh receptor agonists for the treatment of fertility disorders |
WO2010144571A1 (en) | 2009-06-10 | 2010-12-16 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011033265A1 (en) | 2009-09-18 | 2011-03-24 | Almac Discovery Limited | Pharmaceutical compounds |
WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
US20110112067A1 (en) | 2009-11-09 | 2011-05-12 | Universitat Des Saarlandes | Inhibitors of the Human Aldosterone Sythase CYP11B2 |
WO2011089400A1 (en) | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
WO2011112766A2 (en) | 2010-03-10 | 2011-09-15 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
WO2011113606A1 (en) | 2010-03-18 | 2011-09-22 | Institut Pasteur Korea | Anti-infective compounds |
WO2011113862A1 (en) | 2010-03-18 | 2011-09-22 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines |
WO2011121137A1 (en) | 2010-04-02 | 2011-10-06 | Euroscreen S.A. | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011131576A1 (en) | 2010-04-20 | 2011-10-27 | Università Degli Studi Di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
WO2011160548A1 (zh) | 2010-06-25 | 2011-12-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途 |
WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
WO2012007345A2 (en) | 2010-07-12 | 2012-01-19 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyrimidines and -pyridines |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
US8115000B2 (en) | 2006-06-22 | 2012-02-14 | Mallinckrodt Llc | Pyrazine derivatives and uses thereof in renal monitoring |
WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2012042042A1 (en) | 2010-09-30 | 2012-04-05 | Oryzon Genomics S.A. | Selective lsd1 and dual lsd1/mao-b inhibitors for modulating diseases associated with alterations in protein conformation |
WO2012047852A2 (en) | 2010-10-07 | 2012-04-12 | The J. David Gladstone Institutes | Compositions and methods for modulating immunodeficiency virus transcription |
WO2012054233A1 (en) | 2010-10-18 | 2012-04-26 | E. I. Du Pont De Nemours And Company | Nematocidal sulfonamides |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
WO2012052730A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Use of pi3k inibitors for the treatment of obesity, steatosis and ageing |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
WO2012080234A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
WO2012080236A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080230A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080232A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080476A1 (en) | 2010-12-17 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
WO2012088411A1 (en) | 2010-12-22 | 2012-06-28 | Pamlico Pharmaceutical Inc. | 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives |
WO2012100229A2 (en) | 2011-01-21 | 2012-07-26 | The General Hospital Corporation | Compositions and methods for cardiovascular disease |
WO2012107499A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
US20120220582A1 (en) | 2008-12-08 | 2012-08-30 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
WO2012135113A2 (en) | 2011-03-25 | 2012-10-04 | Glaxosmithkline Llc | Cyclopropylamines as lsd1 inhibitors |
WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
US20120322877A1 (en) | 2009-08-18 | 2012-12-20 | Casero Robert A | (bis)urea and (bis)thiorea compounds as eipgenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2012176856A2 (en) | 2011-06-24 | 2012-12-27 | Ishihara Sangyo Kaisha, Ltd. | Pesticide |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
US8349210B2 (en) | 2008-06-27 | 2013-01-08 | Transitions Optical, Inc. | Mesogenic stabilizers |
WO2013010380A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2013022047A1 (ja) | 2011-08-09 | 2013-02-14 | 武田薬品工業株式会社 | シクロプロパンアミン化合物 |
WO2013025805A1 (en) | 2011-08-15 | 2013-02-21 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
WO2013033688A1 (en) | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
WO2013033515A1 (en) | 2011-09-02 | 2013-03-07 | Promega Corporation | Compounds and methods for assaying redox state of metabolically active cells and methods for measuring nad(p)/nad(p)h |
WO2013053690A1 (en) | 2011-10-10 | 2013-04-18 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
WO2013057320A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
WO2013057322A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
US20130109751A1 (en) | 2011-10-28 | 2013-05-02 | Mesogenics S.R.L. | Lsd-1 enzyme inhibitors for inducing osteogenic differentiation |
WO2013074390A1 (en) | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
WO2013085877A1 (en) | 2011-12-05 | 2013-06-13 | Brandeis University | Treatment of amyloidosis by compounds that regulate retromer stabilization |
US20130217878A1 (en) | 2010-09-29 | 2013-08-22 | Kissei Pharmaceutical Co., Ltd. | (aza)indolizine derivative and pharmaceutical use thereof |
WO2013147711A1 (en) | 2012-03-30 | 2013-10-03 | Agency For Science, Technology And Research | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
WO2014002051A2 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
WO2014009296A1 (en) | 2012-07-13 | 2014-01-16 | Ucb Pharma S.A. | Imidazopyrazine derivatives as modulators of tnf activity |
CA2887598A1 (en) | 2012-10-12 | 2014-04-17 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
WO2014085613A1 (en) | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するlsd1選択的阻害薬 |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
CN103893163A (zh) | 2014-03-28 | 2014-07-02 | 中国药科大学 | 2-([1,1’-联苯]-4-基)-2-氧代乙基 4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
CN103933036A (zh) | 2013-01-23 | 2014-07-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-α]吡啶-3-乙酰胺衍生物在制备防治PTSD的药物中的用途 |
CN103961340A (zh) | 2014-04-30 | 2014-08-06 | 中国科学院海洋研究所 | 一类lsd1抑制剂及其应用 |
WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
WO2014138791A1 (en) | 2013-03-13 | 2014-09-18 | Australian Nuclear Science And Technology Organisation | Transgenic non-human organisms with non-functional tspo genes |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
CN104119280A (zh) | 2014-06-27 | 2014-10-29 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
US20140343118A1 (en) | 2013-03-14 | 2014-11-20 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
WO2014194280A2 (en) | 2013-05-30 | 2014-12-04 | The Board of Regents of the Nevada System of Higher Education on behalf of the University of | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
WO2014205213A1 (en) | 2013-06-19 | 2014-12-24 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
US20150065434A1 (en) | 2013-08-29 | 2015-03-05 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
US20150133564A1 (en) | 2013-11-13 | 2015-05-14 | Snu R&Db Foundation | Novel compound, preparing method thereof, and use thereof as inhibitors of histone demethylase |
WO2015089192A1 (en) | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
US20150225379A1 (en) | 2014-02-13 | 2015-08-13 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US20150225394A1 (en) | 2014-02-13 | 2015-08-13 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US20150225375A1 (en) | 2014-02-13 | 2015-08-13 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2015156417A1 (en) | 2014-04-11 | 2015-10-15 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
WO2015181380A1 (en) | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
US20160009712A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US20160009711A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US20160289238A1 (en) | 2015-04-03 | 2016-10-06 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7013068A (ja) | 1969-09-17 | 1971-03-19 | ||
US4537889A (en) | 1982-12-27 | 1985-08-27 | Eli Lilly And Company | Inotropic agents |
US4614810A (en) | 1984-09-24 | 1986-09-30 | Pennwalt Corporation | 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof |
US4625040A (en) | 1984-09-24 | 1986-11-25 | Pennwalt Corporation | N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives |
JPH032778Y2 (ja) | 1986-12-15 | 1991-01-24 | ||
JP2844351B2 (ja) | 1989-07-13 | 1999-01-06 | 株式会社科薬 | 安定なポリミキシン系抗生物質水性溶液 |
JP2923139B2 (ja) | 1992-10-05 | 1999-07-26 | 三井化学株式会社 | 製 剤 |
US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
WO2001022791A2 (en) | 1999-09-28 | 2001-04-05 | Panacea Biotec Limited | Controlled release compositions comprising nimesulide |
SE9903611D0 (sv) | 1999-10-06 | 1999-10-06 | Astra Ab | Novel compounds III |
AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
AU2002212530B2 (en) | 2000-11-10 | 2006-08-17 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for GABA receptors |
EP1576150A4 (en) | 2002-10-16 | 2006-05-03 | Univ Texas | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICACY OF ACTIVE SUBSTANCES FROM A BIOLOGICAL VIEWPOINT |
ATE516019T1 (de) | 2004-05-11 | 2011-07-15 | Egalet Ltd | Quellbare dosierform mit gellan-gummit |
WO2006026703A2 (en) | 2004-09-02 | 2006-03-09 | Smithkline Beecham Corporation | Chemical compounds |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
TWI255587B (en) | 2005-07-04 | 2006-05-21 | Quanta Comp Inc | Multi-frequency planar antenna |
CN101300233A (zh) | 2005-09-09 | 2008-11-05 | 先灵公司 | 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂 |
EA017290B1 (ru) | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
CA2633536A1 (en) | 2005-12-27 | 2007-07-05 | F. Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives |
CA2668689C (en) | 2006-11-08 | 2015-12-29 | Neurocrine Biosciences Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
WO2008063910A2 (en) | 2006-11-08 | 2008-05-29 | Novavax, Inc. | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
JP5612860B2 (ja) | 2007-03-09 | 2014-10-22 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのイミダゾ[1,5−a]ピリジン誘導体 |
ES2648037T3 (es) | 2007-05-21 | 2017-12-28 | Toray Industries, Inc. | Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral |
US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
KR20090022616A (ko) | 2007-08-31 | 2009-03-04 | 한올제약주식회사 | 베실산클로피도그렐 함유 경구투여용 약제 |
KR20170021904A (ko) | 2007-10-12 | 2017-02-28 | 노파르티스 아게 | 스핑고신 1 포스페이트 (s1p) 수용체 조절제를 포함하는 조성물 |
KR100988233B1 (ko) | 2007-12-26 | 2010-10-18 | 한미홀딩스 주식회사 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
KR20150140418A (ko) | 2008-03-12 | 2015-12-15 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로사이클 융합 감마-카볼라인 고체 |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
WO2010090991A1 (en) | 2009-02-04 | 2010-08-12 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
TR200900879A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler |
CN102361872B (zh) | 2009-02-13 | 2014-12-03 | 拜耳知识产权有限责任公司 | 作为akt抑制剂的稠合嘧啶 |
WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
MX2012012145A (es) | 2010-04-28 | 2012-11-21 | Daiichi Sankyo Co Ltd | Compuestos [5, 6] heterociclico. |
CN102247321A (zh) | 2010-05-20 | 2011-11-23 | 上海亚盛医药科技有限公司 | 一种阿朴棉子酚酮自乳化药物传递系统及其制备方法 |
WO2011149438A1 (en) | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
CN101987082B (zh) | 2010-07-16 | 2013-04-03 | 钟术光 | 固体制剂及其制备方法 |
CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
CN102397552B (zh) | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
PT2630146T (pt) | 2010-10-21 | 2020-07-20 | Medivation Tech Llc | Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino |
BRPI1100101B1 (pt) | 2011-01-28 | 2020-10-20 | Universidade De São Paulo Usp | anel oito articulado |
AU2012265842A1 (en) | 2011-06-07 | 2014-01-23 | SPAI Group Ltd. | Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof |
CL2014000988A1 (es) | 2011-10-20 | 2014-11-03 | Oryzon Genomics Sa | Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia. |
CA2866450C (en) | 2012-03-07 | 2020-02-18 | Merck Patent Gmbh | Triazolopyrazine derivatives |
CN102579381B (zh) | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | 盐酸胍法辛缓释制剂及其制备方法 |
PT3176170T (pt) * | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
CN102772444A (zh) | 2012-07-06 | 2012-11-14 | 周明千 | 中药超微破壁口服片剂饮片的加工方法 |
US9738636B2 (en) | 2012-09-28 | 2017-08-22 | Vanderbilt University | Fused heterocyclic compounds as selective BMP inhibitors |
SG11201502527UA (en) | 2012-10-05 | 2015-04-29 | Rigel Pharmaceuticals Inc | Gdf-8 inhibitors |
US9707275B2 (en) | 2012-12-19 | 2017-07-18 | Wockhardt Limited | Stable aqueous composition comprising human insulin or an analogue or derivative thereof |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
JP2016517434A (ja) | 2013-03-14 | 2016-06-16 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
JP6603213B2 (ja) | 2013-06-21 | 2019-11-06 | マイオカーディア,インク | 心臓状態に対するピリミジンジオン化合物 |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
EP3043778B1 (en) | 2013-09-13 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2015217073B2 (en) * | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2015145145A1 (en) | 2014-03-24 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising lapatinib |
CN106458994B (zh) | 2014-04-02 | 2019-09-13 | 百时美施贵宝公司 | 联芳激酶抑制剂 |
EP2933002A1 (en) | 2014-04-11 | 2015-10-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
EP2929884A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
CN104173313B (zh) | 2014-08-25 | 2017-05-17 | 杭州朱养心药业有限公司 | 利伐沙班片剂药物组合物 |
JP6653116B2 (ja) | 2014-08-27 | 2020-02-26 | 日本ケミファ株式会社 | オルメサルタンのプロドラッグ製剤 |
UA122061C2 (uk) | 2014-10-08 | 2020-09-10 | Ф. Хоффманн-Ля Рош Аг | Похідні спіродіаміну як інгібітори альдостеронсинтази |
CN107438614B (zh) | 2015-04-03 | 2020-01-31 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
CA2981584A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
CN105232488B (zh) | 2015-10-15 | 2021-05-04 | 上海凌凯医药科技有限公司 | 一种含有利伐沙班的固体药物组合物 |
KR20180117602A (ko) | 2015-12-29 | 2018-10-29 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
JPWO2017130933A1 (ja) | 2016-01-25 | 2018-11-29 | 国立大学法人 熊本大学 | 神経変性疾患治療剤 |
EP3445339B1 (en) | 2016-04-22 | 2023-08-23 | Incyte Corporation | Formulations of an lsd1 inhibitor |
JP2020511424A (ja) | 2017-01-18 | 2020-04-16 | ヴァンダービルト ユニバーシティーVanderbilt University | 選択的bmp阻害としての縮合複素環式化合物 |
CN109963854B (zh) | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
-
2015
- 2015-02-12 AU AU2015217073A patent/AU2015217073B2/en active Active
- 2015-02-12 SG SG10201908028S patent/SG10201908028SA/en unknown
- 2015-02-12 CN CN201580017095.0A patent/CN106164066B/zh active Active
- 2015-02-12 CA CA2939082A patent/CA2939082C/en active Active
- 2015-02-12 JP JP2016551710A patent/JP6602778B2/ja active Active
- 2015-02-12 PL PL15706634T patent/PL3105218T3/pl unknown
- 2015-02-12 CR CR20200199A patent/CR20200199A/es unknown
- 2015-02-12 DK DK15706634T patent/DK3105218T3/da active
- 2015-02-12 SG SG10201806849WA patent/SG10201806849WA/en unknown
- 2015-02-12 SI SI201530920T patent/SI3105218T1/sl unknown
- 2015-02-12 RS RS20191486A patent/RS59559B1/sr unknown
- 2015-02-12 HU HUE15706634A patent/HUE046273T2/hu unknown
- 2015-02-12 EP EP15706634.1A patent/EP3105218B1/en active Active
- 2015-02-12 ME MEP-2019-327A patent/ME03654B/me unknown
- 2015-02-12 WO PCT/US2015/015706 patent/WO2015123465A1/en active Application Filing
- 2015-02-12 US US14/620,903 patent/US9670210B2/en active Active
- 2015-02-12 KR KR1020167025508A patent/KR102421235B1/ko active IP Right Grant
- 2015-02-12 PE PE2016001466A patent/PE20161573A1/es unknown
- 2015-02-12 SG SG11201606689VA patent/SG11201606689VA/en unknown
- 2015-02-12 PT PT157066341T patent/PT3105218T/pt unknown
- 2015-02-12 MY MYPI2016001506A patent/MY183499A/en unknown
- 2015-02-12 MX MX2016010395A patent/MX2016010395A/es active IP Right Grant
- 2015-02-12 ES ES19190494T patent/ES2901711T3/es active Active
- 2015-02-12 EP EP19190494.5A patent/EP3626713B1/en active Active
- 2015-02-12 TW TW104104827A patent/TWI685483B/zh active
- 2015-02-12 LT LT15706634T patent/LT3105218T/lt unknown
- 2015-02-12 CN CN201911356925.9A patent/CN111454188A/zh active Pending
- 2015-02-12 TW TW109101686A patent/TWI741478B/zh active
- 2015-02-12 CR CR20160396A patent/CR20160396A/es unknown
- 2015-02-12 ES ES15706634T patent/ES2760261T3/es active Active
- 2015-02-12 UA UAA201609400A patent/UA126541C2/uk unknown
-
2016
- 2016-08-07 IL IL247134A patent/IL247134B/en active IP Right Grant
- 2016-08-10 MX MX2020012046A patent/MX2020012046A/es unknown
- 2016-08-11 CL CL2016002027A patent/CL2016002027A1/es unknown
- 2016-08-11 PH PH12016501601A patent/PH12016501601A1/en unknown
- 2016-09-09 ZA ZA2016/06275A patent/ZA201606275B/en unknown
- 2016-09-09 EC ECIEPI201673190A patent/ECSP16073190A/es unknown
-
2017
- 2017-04-26 US US15/497,887 patent/US10174030B2/en active Active
-
2018
- 2018-11-19 US US16/195,026 patent/US10717737B2/en active Active
-
2019
- 2019-08-01 AU AU2019210624A patent/AU2019210624B2/en active Active
- 2019-10-09 JP JP2019185892A patent/JP6883635B2/ja active Active
- 2019-11-29 HR HRP20192167TT patent/HRP20192167T1/hr unknown
- 2019-12-12 CY CY20191101308T patent/CY1122415T1/el unknown
-
2020
- 2020-06-09 US US16/897,051 patent/US11247992B2/en active Active
- 2020-09-06 IL IL277167A patent/IL277167B/en unknown
Patent Citations (272)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988004298A1 (en) | 1986-12-05 | 1988-06-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 8-alkylaminoimidazo[1,2-a]pyrazines and derivatives, their preparation and their application in therapy |
EP0404190A1 (en) | 1989-06-23 | 1990-12-27 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
EP0430385A2 (en) | 1989-11-30 | 1991-06-05 | Schering Aktiengesellschaft | Substituted 1,2,4-triazolo-[4,3-a]pyridines, and substituted N'-(2-pyridyl)-hydrazones, and their use as herbicides |
FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
WO1993025553A1 (en) | 1992-06-17 | 1993-12-23 | The Upjohn Company | Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents |
WO1994018198A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Aktiengesellschaft | Imidazoazine |
US5658857A (en) | 1993-02-15 | 1997-08-19 | Bayer Aktiengesellschaft | Imidazoazines |
WO1995012594A1 (fr) | 1993-11-05 | 1995-05-11 | Rhone-Poulenc Rorer S.A. | 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE ANTAGONISTES DU RECEPTEUR NMDA |
WO1999024434A1 (en) | 1997-11-11 | 1999-05-20 | Ono Pharmaceutical Co., Ltd. | Fused pyrazine compounds |
JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP2000319278A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP2001006877A (ja) | 1999-06-21 | 2001-01-12 | Toray Ind Inc | 発光素子 |
JP2001035664A (ja) | 1999-07-21 | 2001-02-09 | Mitsui Chemicals Inc | 有機電界発光素子 |
JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
WO2001027119A2 (de) | 1999-10-08 | 2001-04-19 | Grünenthal GmbH | Substanzbibliothek enthaltend bicyclische imidazo-5-yl-amine und/oder bicyclische imidazo-3-yl-amine |
JP2001114780A (ja) | 1999-10-18 | 2001-04-24 | Yakult Honsha Co Ltd | 三環性縮合イミダゾール誘導体 |
US20020151549A1 (en) | 2000-04-27 | 2002-10-17 | Masahiko Hayakawa | Imidazopyridine derivatives |
WO2001083481A1 (fr) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'imidazopyridine |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
US20040023972A1 (en) | 2000-10-13 | 2004-02-05 | Gruenenthal Gmbh | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |
WO2002034748A1 (en) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Imidazopyridine derivatives |
WO2002038562A1 (fr) | 2000-11-08 | 2002-05-16 | Sumitomo Chemical Takeda Agro Company, Limited | Derives de triazolone bicycliques et herbicides contenant ces derniers |
US20040058938A1 (en) | 2000-12-13 | 2004-03-25 | Oliver Cullmann | Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds |
WO2002051831A1 (en) | 2000-12-23 | 2002-07-04 | Aventis Pharma Deutschland Gmbh | Oxybenzamides derivatives as factor xa inhibitors |
US20040082781A1 (en) | 2001-02-08 | 2004-04-29 | Shigeki Hibi | Bicyclic nitrogenous fused-ring compound |
WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
US20040082635A1 (en) | 2001-06-26 | 2004-04-29 | Hiromasa Hashimoto | Fused cyclic compounds and medicinal use thereof |
WO2003006471A1 (en) | 2001-07-13 | 2003-01-23 | Neurogen Corporation | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
WO2003044021A2 (en) | 2001-11-16 | 2003-05-30 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
WO2003062392A2 (en) | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
WO2004021989A2 (en) | 2002-09-06 | 2004-03-18 | Biogen Idec Ma Inc. | Imidazolopyridines and methods of making and using the same |
WO2004058762A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2004074290A1 (en) | 2003-02-20 | 2004-09-02 | Merck Sharp & Dohme Limited | Substituted amino heterocycles as vr-1 antagonists for treating pain |
US20050009832A1 (en) | 2003-02-20 | 2005-01-13 | Sugen, Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US20040220189A1 (en) | 2003-02-20 | 2004-11-04 | Sugen, Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors |
US20060178399A1 (en) | 2003-03-14 | 2006-08-10 | Rena Nishizawa | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
WO2004089380A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of fused 1,2,4-triazoles |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
WO2004096131A2 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2004108692A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) |
WO2005007658A2 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2005025558A1 (en) | 2003-09-12 | 2005-03-24 | Applied Reserach Systems Ars Holding N.V. | Sulfonamide derivatives for the treatment of diabetes |
JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
WO2005035532A1 (en) | 2003-10-10 | 2005-04-21 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
WO2005042537A1 (en) | 2003-10-22 | 2005-05-12 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
WO2005044793A2 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
US20080249154A1 (en) | 2003-12-26 | 2008-10-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates |
US20070191395A1 (en) | 2004-02-16 | 2007-08-16 | Katsuhiro Kawakami | Heterocyclic compounds having antifungal activity |
WO2005097052A1 (en) | 2004-03-30 | 2005-10-20 | The Procter & Gamble Company | Keratin dyeing compositions bicyclic 5-6 heteroaromatic dyeing compounds with one ring nitrogen junction |
US7468375B2 (en) * | 2004-04-26 | 2008-12-23 | Pfizer Inc. | Inhibitors of the HIV integrase enzyme |
WO2006015263A2 (en) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
WO2006018727A2 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds useful for the treatment of inflammation |
WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
WO2006057946A2 (en) | 2004-11-22 | 2006-06-01 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer agents and prodrugs thereof |
WO2006058752A1 (en) | 2004-12-01 | 2006-06-08 | Laboratoires Serono S.A. | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
WO2006073938A2 (en) | 2004-12-30 | 2006-07-13 | East Carolina University | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
WO2006074041A2 (en) | 2004-12-31 | 2006-07-13 | National Health Research Institutes | Anti-tumor compounds |
US20060194842A1 (en) | 2005-02-22 | 2006-08-31 | Chikara Uchida | Oxyindole derivatives |
WO2006113704A2 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
WO2006135795A1 (en) | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006135667A1 (en) | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Imidiazo -and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2006131003A1 (en) | 2005-06-09 | 2006-12-14 | Oncalis Ag | Angiogenesis inhibitors |
WO2006138734A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
WO2006138657A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
WO2006138695A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
US20070004772A1 (en) | 2005-06-17 | 2007-01-04 | Chongqing Sun | Triazolopyridine cannabinoid receptor 1 antagonists |
WO2007022529A2 (en) | 2005-08-19 | 2007-02-22 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2007028051A2 (en) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
WO2007058942A2 (en) | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2007074491A1 (en) | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
WO2007095588A1 (en) | 2006-02-14 | 2007-08-23 | Novartis Ag | Pi-3 kinase inhibitors and methods of their use |
WO2007113226A1 (en) | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
WO2007145921A1 (en) | 2006-06-06 | 2007-12-21 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
US8115000B2 (en) | 2006-06-22 | 2012-02-14 | Mallinckrodt Llc | Pyrazine derivatives and uses thereof in renal monitoring |
WO2007149478A2 (en) | 2006-06-22 | 2007-12-27 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
WO2008005262A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
WO2008005423A1 (en) | 2006-07-03 | 2008-01-10 | Cambrex Charles City, Inc. | Improved method of making sufentanil |
WO2008005908A2 (en) | 2006-07-07 | 2008-01-10 | Forest Laboratories Holdings Limited | Pyridoimidazole derivatives |
WO2008008539A2 (en) | 2006-07-14 | 2008-01-17 | Amgen Inc. | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
US20090318436A1 (en) | 2006-07-14 | 2009-12-24 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2008011560A2 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
DE102006041292A1 (de) | 2006-09-01 | 2008-03-06 | Henkel Kgaa | Wasserstoffperoxid-Aktivierung mit N-Heterocyclen |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
WO2008045393A2 (en) | 2006-10-11 | 2008-04-17 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use therof |
WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
WO2008064157A1 (en) | 2006-11-22 | 2008-05-29 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
WO2008065198A1 (en) | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
US20100113441A1 (en) | 2007-03-16 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazopyrimidines and triazolopyrimidines |
US20130040946A1 (en) | 2007-03-16 | 2013-02-14 | Bayer Intellectual Property Gmbh | Substituted imidazopyrimidines and triazolopyrimidines |
WO2008113559A2 (en) | 2007-03-21 | 2008-09-25 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as cns active compounds |
WO2008125111A1 (en) | 2007-04-16 | 2008-10-23 | Leo Pharma A/S | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
WO2008141239A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
US20090203690A1 (en) | 2007-06-08 | 2009-08-13 | Abbott Laboratories | 5-substituted indazoles as kinase inhibitors |
WO2008154241A1 (en) | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
WO2008156614A2 (en) | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2008157752A1 (en) | 2007-06-21 | 2008-12-24 | Incyte Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
WO2009010530A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
WO2009017701A2 (en) | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
FR2920090A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier. |
FR2920091A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier. |
WO2009045753A1 (en) | 2007-10-01 | 2009-04-09 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
WO2009047514A1 (en) | 2007-10-10 | 2009-04-16 | Cancer Research Technology Limited | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
WO2009047563A1 (en) | 2007-10-11 | 2009-04-16 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
WO2009085980A1 (en) | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents |
WO2009091374A2 (en) | 2008-01-15 | 2009-07-23 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2009114512A1 (en) | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
WO2009114180A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
US20110105457A1 (en) | 2008-04-18 | 2011-05-05 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on pi3k |
WO2009128520A1 (ja) | 2008-04-18 | 2009-10-22 | 塩野義製薬株式会社 | P13k阻害活性を有する複素環化合物 |
US8349210B2 (en) | 2008-06-27 | 2013-01-08 | Transitions Optical, Inc. | Mesogenic stabilizers |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010019899A1 (en) | 2008-08-14 | 2010-02-18 | Takeda Pharmaceutical Company Limited | cMET INHIBITORS |
JP2010070503A (ja) | 2008-09-19 | 2010-04-02 | Daiichi Sankyo Co Ltd | 抗真菌作用2−アミノトリアゾロピリジン誘導体 |
WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
US20120220582A1 (en) | 2008-12-08 | 2012-08-30 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
US20120004262A1 (en) | 2009-01-21 | 2012-01-05 | Nathalie Guibourt | Phenylcyclopropylamine derivatives and their medical use |
WO2010088368A2 (en) | 2009-01-29 | 2010-08-05 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2010091067A2 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2010104306A2 (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
WO2010108059A1 (en) | 2009-03-20 | 2010-09-23 | Incyte Corporation | Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor |
WO2010113942A1 (ja) | 2009-03-31 | 2010-10-07 | キッセイ薬品工業株式会社 | インドリジン誘導体及びその医薬用途 |
WO2010119264A1 (en) | 2009-04-16 | 2010-10-21 | Centro Nacional De Investigaciones Oncólogicas (Cnio) | Imidazopyrazines for use as kinase inhibitors |
WO2010136438A1 (en) | 2009-05-27 | 2010-12-02 | N.V. Organon | (dihydro) imidazoiso (5, 1-a) quinolines as fsh receptor agonists for the treatment of fertility disorders |
WO2010144571A1 (en) | 2009-06-10 | 2010-12-16 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US20120322877A1 (en) | 2009-08-18 | 2012-12-20 | Casero Robert A | (bis)urea and (bis)thiorea compounds as eipgenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2011033265A1 (en) | 2009-09-18 | 2011-03-24 | Almac Discovery Limited | Pharmaceutical compounds |
US20120283266A1 (en) | 2009-09-25 | 2012-11-08 | Ortega Munoz Alberto | Lysine specific demethylase-1 inhibitors and their use |
WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
US20110112067A1 (en) | 2009-11-09 | 2011-05-12 | Universitat Des Saarlandes | Inhibitors of the Human Aldosterone Sythase CYP11B2 |
WO2011089400A1 (en) | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
US20130095067A1 (en) | 2010-02-24 | 2013-04-18 | Jonathan Alleman Baker | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
WO2011112766A2 (en) | 2010-03-10 | 2011-09-15 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
WO2011113862A1 (en) | 2010-03-18 | 2011-09-22 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines |
WO2011113606A1 (en) | 2010-03-18 | 2011-09-22 | Institut Pasteur Korea | Anti-infective compounds |
WO2011121137A1 (en) | 2010-04-02 | 2011-10-06 | Euroscreen S.A. | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
US20130090386A1 (en) | 2010-04-19 | 2013-04-11 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
US20140213657A1 (en) | 2010-04-19 | 2014-07-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
US20130035377A1 (en) | 2010-04-20 | 2013-02-07 | Università Degli Studi Di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylases lsd1 and/or lsd2 |
WO2011131576A1 (en) | 2010-04-20 | 2011-10-27 | Università Degli Studi Di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
WO2011160548A1 (zh) | 2010-06-25 | 2011-12-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途 |
US20130203754A1 (en) | 2010-06-25 | 2013-08-08 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof |
WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
WO2012007345A2 (en) | 2010-07-12 | 2012-01-19 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyrimidines and -pyridines |
WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
US20130197013A1 (en) | 2010-07-29 | 2013-08-01 | Mathew Colin Thor Fyfe | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
CN103124724A (zh) | 2010-07-29 | 2013-05-29 | 奥瑞泽恩基因组学股份有限公司 | Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途 |
US20130231342A1 (en) | 2010-07-29 | 2013-09-05 | Oryzon Fenomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
US20140011857A1 (en) | 2010-09-10 | 2014-01-09 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
US20130217878A1 (en) | 2010-09-29 | 2013-08-22 | Kissei Pharmaceutical Co., Ltd. | (aza)indolizine derivative and pharmaceutical use thereof |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012042042A1 (en) | 2010-09-30 | 2012-04-05 | Oryzon Genomics S.A. | Selective lsd1 and dual lsd1/mao-b inhibitors for modulating diseases associated with alterations in protein conformation |
US20120108500A1 (en) | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
WO2012047852A2 (en) | 2010-10-07 | 2012-04-12 | The J. David Gladstone Institutes | Compositions and methods for modulating immunodeficiency virus transcription |
WO2012054233A1 (en) | 2010-10-18 | 2012-04-26 | E. I. Du Pont De Nemours And Company | Nematocidal sulfonamides |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
WO2012052730A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Use of pi3k inibitors for the treatment of obesity, steatosis and ageing |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
US20140256742A1 (en) | 2010-11-30 | 2014-09-11 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
WO2012080476A1 (en) | 2010-12-17 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases |
WO2012080236A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080230A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080232A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080234A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
WO2012088411A1 (en) | 2010-12-22 | 2012-06-28 | Pamlico Pharmaceutical Inc. | 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives |
WO2012100229A2 (en) | 2011-01-21 | 2012-07-26 | The General Hospital Corporation | Compositions and methods for cardiovascular disease |
US20150232436A1 (en) | 2011-02-08 | 2015-08-20 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2012107499A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
US20140018393A1 (en) | 2011-03-25 | 2014-01-16 | Glaxo Smith Kline LLC | Cyclopropylamines as lsd1 inhibitors |
US8853408B2 (en) | 2011-03-25 | 2014-10-07 | Glaxosmithkline Intellectual Property (No. 2) Limited | Cyclopropylamines as LSD1 inhibitors |
WO2012135113A2 (en) | 2011-03-25 | 2012-10-04 | Glaxosmithkline Llc | Cyclopropylamines as lsd1 inhibitors |
CA2831143A1 (en) | 2011-03-25 | 2012-10-04 | Glaxosmithkline Intellectual Property Development Limited | Cyclopropylamines as lsd1 inhibitors |
WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
US20140329833A1 (en) | 2011-05-19 | 2014-11-06 | Oryzon Genomics, S.A | Lysine demethylase inhibitors for inflammatory diseases or conditions |
WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
WO2012176856A2 (en) | 2011-06-24 | 2012-12-27 | Ishihara Sangyo Kaisha, Ltd. | Pesticide |
WO2013010380A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20140228405A1 (en) | 2011-08-09 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Cyclopropaneamine compound |
CA2844525A1 (en) | 2011-08-09 | 2013-02-14 | Takeda Pharmaceutical Company Limited | Cyclopropaneamine compound |
WO2013022047A1 (ja) | 2011-08-09 | 2013-02-14 | 武田薬品工業株式会社 | シクロプロパンアミン化合物 |
EP2743256A1 (en) | 2011-08-09 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Cyclopropaneamine compound |
WO2013025805A1 (en) | 2011-08-15 | 2013-02-21 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
US20140094445A1 (en) | 2011-08-15 | 2014-04-03 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
US20140206757A1 (en) | 2011-09-01 | 2014-07-24 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
WO2013033688A1 (en) | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
WO2013033515A1 (en) | 2011-09-02 | 2013-03-07 | Promega Corporation | Compounds and methods for assaying redox state of metabolically active cells and methods for measuring nad(p)/nad(p)h |
WO2013053690A1 (en) | 2011-10-10 | 2013-04-18 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
WO2013057322A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
WO2013057320A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
US20130109751A1 (en) | 2011-10-28 | 2013-05-02 | Mesogenics S.R.L. | Lsd-1 enzyme inhibitors for inducing osteogenic differentiation |
WO2013074390A1 (en) | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
WO2013085877A1 (en) | 2011-12-05 | 2013-06-13 | Brandeis University | Treatment of amyloidosis by compounds that regulate retromer stabilization |
WO2013147711A1 (en) | 2012-03-30 | 2013-10-03 | Agency For Science, Technology And Research | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
WO2014002051A2 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
WO2014009296A1 (en) | 2012-07-13 | 2014-01-16 | Ucb Pharma S.A. | Imidazopyrazine derivatives as modulators of tnf activity |
WO2014058071A1 (ja) | 2012-10-12 | 2014-04-17 | 武田薬品工業株式会社 | シクロプロパンアミン化合物およびその用途 |
CA2887598A1 (en) | 2012-10-12 | 2014-04-17 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するlsd1選択的阻害薬 |
WO2014085613A1 (en) | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
WO2014086790A1 (en) | 2012-12-05 | 2014-06-12 | Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
CN103933036A (zh) | 2013-01-23 | 2014-07-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-α]吡啶-3-乙酰胺衍生物在制备防治PTSD的药物中的用途 |
WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
WO2014138791A1 (en) | 2013-03-13 | 2014-09-18 | Australian Nuclear Science And Technology Organisation | Transgenic non-human organisms with non-functional tspo genes |
US20140343118A1 (en) | 2013-03-14 | 2014-11-20 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
WO2014194280A2 (en) | 2013-05-30 | 2014-12-04 | The Board of Regents of the Nevada System of Higher Education on behalf of the University of | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
WO2014205213A1 (en) | 2013-06-19 | 2014-12-24 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
US20150065434A1 (en) | 2013-08-29 | 2015-03-05 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
US20150065495A1 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted- 1h-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (lsd1) inhibitors |
US20150133564A1 (en) | 2013-11-13 | 2015-05-14 | Snu R&Db Foundation | Novel compound, preparing method thereof, and use thereof as inhibitors of histone demethylase |
WO2015089192A1 (en) | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
US20150225379A1 (en) | 2014-02-13 | 2015-08-13 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US20150225394A1 (en) | 2014-02-13 | 2015-08-13 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US20150225375A1 (en) | 2014-02-13 | 2015-08-13 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
CN103893163A (zh) | 2014-03-28 | 2014-07-02 | 中国药科大学 | 2-([1,1’-联苯]-4-基)-2-氧代乙基 4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
WO2015156417A1 (en) | 2014-04-11 | 2015-10-15 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
CN103961340A (zh) | 2014-04-30 | 2014-08-06 | 中国科学院海洋研究所 | 一类lsd1抑制剂及其应用 |
WO2015181380A1 (en) | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
CN104119280A (zh) | 2014-06-27 | 2014-10-29 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
US20160009712A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US20160009720A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US20160009721A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US20160009711A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US20160289238A1 (en) | 2015-04-03 | 2016-10-06 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
Non-Patent Citations (185)
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10513493B2 (en) | 2014-02-13 | 2019-12-24 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10174030B2 (en) | 2014-02-13 | 2019-01-08 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10717737B2 (en) | 2014-02-13 | 2020-07-21 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10676457B2 (en) | 2014-02-13 | 2020-06-09 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10300051B2 (en) | 2014-02-13 | 2019-05-28 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US11247992B2 (en) | 2014-02-13 | 2022-02-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9994546B2 (en) | 2014-02-13 | 2018-06-12 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10138249B2 (en) | 2014-07-10 | 2018-11-27 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US10047086B2 (en) | 2014-07-10 | 2018-08-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as LSD1 inhibitors |
US10556908B2 (en) | 2014-07-10 | 2020-02-11 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US10640503B2 (en) | 2014-07-10 | 2020-05-05 | Incyte Corporation | Imidazopyridines and imidazopyrazines as LSD1 inhibitors |
US10125133B2 (en) | 2014-07-10 | 2018-11-13 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US10112950B2 (en) | 2014-07-10 | 2018-10-30 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US10800779B2 (en) | 2015-04-03 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US10723700B2 (en) * | 2015-08-12 | 2020-07-28 | Incyte Corporation | Salts of an LSD1 inhibitor |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
US11498900B2 (en) | 2015-08-12 | 2022-11-15 | Incyte Corporation | Salts of an LSD1 inhibitor |
US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
US11512064B2 (en) | 2018-08-31 | 2022-11-29 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11247992B2 (en) | Cyclopropylamines as LSD1 inhibitors | |
US11155532B2 (en) | Cyclopropylamines as LSD1 inhibitors | |
US10300051B2 (en) | Cyclopropylamines as LSD1 inhibitors | |
US10513493B2 (en) | Cyclopropylamines as LSD1 inhibitors | |
EA039196B1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
NZ723817B2 (en) | Cyclopropylamines as lsd1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, LIANGXING;COURTER, JOEL R.;HE, CHUNHONG;AND OTHERS;SIGNING DATES FROM 20150311 TO 20150325;REEL/FRAME:035309/0536 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
AS | Assignment |
Owner name: INCYTE HOLDINGS CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INCYTE CORPORATION;REEL/FRAME:058815/0857 Effective date: 20170123 Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INCYTE CORPORATION;REEL/FRAME:058815/0857 Effective date: 20170123 |